Tetracyclic anthraquinone derivatives

ABSTRACT

Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, 
     
       
         
         
             
             
         
       
         
         
           
             wherein R 1 , R 2 , R 3 , R 4 , R 5 , W, n are defined as in the present application. Also disclosed is a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound and a salt thereof according to the present application possess good anticancer and/or antitumor activity, and good water solubility and stability, as well as good tolerance in animal bodies. Also disclosed is a process for preparing a compound represented by formula (I) of the present application, comprising 
           
         
       
    
                         
reacting a compound represented by formula (II) with a compound represented by formula (III) in the presence of a condensation agent to obtain a compound represented by formula (I).

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is the U.S. National Stage entry of PCT/CN2013/000233,filed Mar. 6, 2013, which claims priority to China Application No.201210055298.7, filed Mar. 6, 2012.

FIELD

The present application relates to the field of organic compounds andmedicinal chemistry. In particular, the present application relates totetracyclic anthraquinone derivatives, preparation processes andapplications thereof.

BACKGROUND

Tetracyclic anthraquinone antibiotics, in particular doxorubicin anddaunorubicin, are widely used anticancer drugs. Doxorubicin hassignificant curative effects on lots of solid tumors including livercancer, gastric cancer, breast cancer, lung cancer, ovary cancer andvarious leukemias. Daunorubicin is one of the most effective drugs fortreating leukemia. However, due to their side effects such as severemyelosuppression, cardiac toxicity, adverse responses in digestivetracts and the like, their clinical applications are somewhatrestricted. Up to now, lots of derivatives of tetracyclic anthraquinoneshave already been separated from the nature or artificially synthesized.

SUMMARY

One aspect of the present application relates to a compound representedby formula (I) and a pharmaceutically acceptable salt thereof,

wherein:

R¹ is selected from the group consisting of H, optionally substitutedalkyl, and optionally substituted alkoxy;

R² is selected from the group consisting of H, optionally substitutedaryl, optionally substituted heteroaryl, optionally substituted(alkyleneoxy)_(m)alkyl, optionally substituted heterocyclyl, optionallysubstituted alkyl, and optionally substituted sulfonyl;

R³ is selected from the group consisting of H, optionally substitutedaryl, optionally substituted heteroaryl, optionally substituted(alkyleneoxy)_(m)alkyl, optionally substituted heterocyclyl, optionallysubstituted alkyl, and optionally substituted sulfonyl;

or NR²R³ represents optionally substituted heterocyclyl;

m is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9,10, and 11;

W is selected from the group consisting of O and NH;

R⁴ is selected from the group consisting of H, F, and optionallysubstituted alkyl;

R⁵ is selected from the group consisting of H, F, optionally substitutedalkyl and OR⁶, wherein R⁶ is selected from the group consisting of H andtetrahydropyran-2-yl;

n is selected from the group consisting of 1, 2 and 3.

Another aspect of the present application relates to a compoundrepresented by formula (I) and a pharmaceutically acceptable saltthereof,

wherein:

R¹ is selected from the group consisting of H, C₁₋₄alkyl, andC₁₋₄alkoxy;

R² is selected from the group consisting of H, aryl, heteroaryl, (C₁₋₄alkyleneoxy)_(m)C₁₋₄alkyl, heterocyclyl, C₁₋₄alkyl, and sulfonyl;

R³ is selected from the group consisting of H, aryl, heteroaryl, (C₁₋₄alkyleneoxy)_(m)C₁₋₄ alkyl, heterocyclyl, C₁₋₄ alkyl, and sulfonyl;

or NR²R³ represents heterocyclyl;

m is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9,10, and 11;

W is selected from the group consisting of O and NH;

R⁴ is selected from the group consisting of H, F and C₁₋₄alkyl;

R⁵ is selected from the group consisting of H, F, C₁₋₄alkyl and OR⁶,wherein R⁶ is selected from the group consisting of H andtetrahydropyran-2-yl; and

n is selected from the group consisting of 1, 2 and 3.

Yet another aspect of the present application relates to a compoundselected from the group consisting of:

No. n NR²R³ 1 3

2 2

3 3

4 2

5 3

6 2

7 3

8 2

9 3

10 2

11 3

12 2

13 3

14 2

15 3

16 2

17 3

18 2

19 3

20 2

21 3

22 2

23 3

24 2

25 3

26 2

27 3

28 2

29 3

30 2

31 3

32 2

33 3

34 2

35 3

36 2

37 3

38 2

39 3

40 2

41 3

42 2

43 3

44 2

45 3

46 2

47 3

48 2

49 3

50 2

51 3

52 2

53 3

54 2

55 3

56 2

57 3

58 2

59 3

60 2

61 3

62 2

63 3

64 2

65 3

66 2 NH₂ 67 3 NH₂ 68 2 NHCH₃ 69 3 NHCH₃ 70 2 NH(CH₃)₂ 71 3 NH(CH₃)₂ 72 2

73 3

74 2

75 2

88 2

90 2

91 2

92 2

93 2

94 2

95 2

-   77)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((4-(2-hydroxyl)ethyl)piperazin-1-yl)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   78)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((3-(morpholin-1-yl)propyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   79)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((4-methyl)piperazin-1-yl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   80)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(4-ethylpiperazin-1-yl)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   81)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   82)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((pyridin-4-yl)methyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   83)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((pyridin-3-yl)methyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   84)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(pyridin-2-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   85)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(pyridin-3-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   86)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(pyridin-4-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   87)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(4-(3-(dimethylamino)propyl)piperazin-1-yl)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   89)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((2-(morpholin-1-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   96)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((2-(morpholin-1-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    phosphate; and-   99)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((2-(morpholin-1-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    hydrochloride.

Still another aspect of the present application relates to a process forpreparing a compound represented by formula (I), comprising:

reacting a compound represented by formula (II) with a compoundrepresented by formula (III) in the presence of a condensation agent toobtain the compound represented by formula (I),

wherein:

-   -   in the compound represented by formula (I), R¹ is selected from        the group consisting of H, C₁₋₄alkyl, and C₁₋₄alkoxy; R² is        selected from the group consisting of H, aryl, heteroaryl, (C₁₋₄        alkyleneoxy)_(m)C₁₋₄ alkyl, heterocyclyl, C₁₋₄alkyl, and        sulfonyl; R³ is selected from the group consisting of H, aryl,        heteroaryl, (C₁₋₄alkyleneoxy)_(m)C₁₋₄alkyl, heterocyclyl,        C₁₋₄alkyl, and sulfonyl; or NR²R³ represents heterocyclyl; m is        selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8,        9, 10, and 11; W is selected from the group consisting of O and        NH; R⁴ is selected from the group consisting of H, F and        C₁₋₄alkyl; R⁵ is selected from the group consisting of H, F,        C₁₋₄alkyl and OR⁶, wherein R⁶ is selected from the group        consisting of H and tetrahydropyran-2-yl; and n is selected from        the group consisting of 1, 2 and 3;

groups represented by R¹, W, R⁴, R⁵ in the compound represented byformula (II) are the same as groups represented by R¹, W, R⁴, R⁵ in thecompound represented by formula (I);

n in the compound represented by formula (III) has the same meanings asn in the compound represented by formula (I); groups represented by R⁷and R⁸ in the compound represented by formula (III) are the same asgroups represented by R² and R³ in the compound represented by formula(I), provided that groups represented by R⁷ and R⁸ do not comprise NH orNH₂; when groups represented by R⁷ and R⁸ comprise NH or NH₂, thecompound represented by formula (III) has an amino-protecting group atN-terminus, and is subject to a deprotection reaction to obtain thecompound represented by formula (I).

Yet another aspect of the present application relates to apharmaceutical composition comprising a compound represented by formula(I) or a pharmaceutically acceptable salt thereof, and apharmaceutically acceptable carrier.

Still another aspect of the present application relates to a formulationcomprising a compound represented by formula (I) or a pharmaceuticallyacceptable salt thereof, and a pharmaceutically acceptable carrier.

Yet another aspect of the present application relates to a method fortreating and/or preventing tumor and/or cancer, comprising administeringto a subject in need thereof a therapeutically effective amount of acompound represented by formula (I) or a pharmaceutically acceptablesalt thereof, or administering a therapeutically effective amount of apharmaceutical composition comprising a compound represented by formula(I) or a pharmaceutically acceptable salt and a pharmaceuticallyacceptable carrier, or administering a therapeutically effective amountof a formulation comprising a compound represented by formula (I) or apharmaceutically acceptable salt and a pharmaceutically acceptablecarrier.

The compound and a salt thereof according to the present applicationpossess good anticancer and/or antitumor activities, and good watersolubility and stability, as well as good tolerance in animal bodies.Therefore, they are prone to being developed as clinical drugs.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows effects of 3′-pyrrolyldoxorubicin on the body weight ofexperimental animals.

FIG. 2 shows effects of the compound in Example 96 according to thepresent application on the body weight of experimental animals.

FIG. 3 shows effects of 3′-pyrrolyldoxorubicin-14-oxo-succinic acidmonoester on the body weight of experimental animals.

DETAILED DESCRIPTION

In the following description, certain specific details are included toprovide a thorough understanding of various disclosed embodiments. Oneof ordinary skill in the relevant art, however, will recognize that theembodiments may be practiced without one or more of these specificdetails, or with other methods, components, materials etc.

Unless the context required otherwise, throughout the specification andclaims which follows, the term “comprise” and variations thereof, suchas “comprises” and “comprising” are to be construed in an open,inclusive sense, which is as “include, but not limited to”.

Reference throughout this specification to “one embodiment”, or “anembodiment”, or “in another embodiment”, or “in some embodiments” meansthat a particular referent feature, structure or characteristicsdescribed in connection with the embodiment is included in at least oneembodiment. Therefore, the appearance of the phrases “in one embodiment”or “in the embodiment” or “in another embodiment” or “in someembodiments” in various places throughout this specification are notnecessarily all referring to the same embodiment. Moreover, theparticular features, structures or characteristics may be combined inany suitable manner in one or more embodiments.

It should be noted that, as used in this specification and the appendedclaims, the singular forms “a”, “an” and “the” include plural referentsunless the context clearly stated otherwise. Therefore, for example, areaction comprising “a catalyst” comprises one catalyst, two or morecatalysts. It should be also noted that the use of “or” means “and/or”unless stated otherwise.

Definitions

Certain chemical groups named herein are preceded by a shorthandnotation indicating the total number of carbon atoms that are to befound in the indicated chemical group. For example, C₇-C₁₂alkyldescribes an alkyl group, as defined below, having a total of 7 to 12carbon atoms, and C₄-C₁₂ cyclohydrocarbylalkyl describes acyclohydrocarbylalkyl group, as defined below, having a total of 4 to 12carbon atoms. The total number of carbon atoms in the shorthand notationdoes not include the carbons that may exist in the substituents of thegroups described.

Accordingly, as used in the specification and appended claims, unlessspecified to the contrary, the following terms have the meaningsindicated:

The term “alkyl”, as used herein, refers to a straight or branchedhydrocarbon chain group consisting solely of carbon and hydrogen,containing no unsaturated bond, having from one to twelve carbon atoms,preferably one to eight or one to six carbon atoms, and which isattached to the rest of the molecule by a single bond, e.g., methyl,ethyl, n-propyl, 1-methylethyl(iso-propyl), n-butyl, n-pentyl,1,1-dimethylethyl(tert-butyl), 3-methylhexyl, 2-methylhexyl, and thelike.

Alkyl group may have one to twelve carbon atoms (whenever it appears inthe present application, a numerical range such as “one to twelve”refers to each integer in the given number range; e.g. “one to twelvecarbon atoms” means that the alkyl group may consist of one carbon atom,two carbon atoms, three carbon atoms, etc., up to and including twelvecarbon atoms, although the present definition also covers the occurrenceof term “alkyl” where no numerical range is designated). Alkyl group mayalso be a medium sized alkyl having one to ten carbon atoms. Alkyl groupmay also be a lower alkyl having one to five carbon atoms. Alkyl groupof compounds of the present application may be designated as “C₁₋₄alkyl” or similar designations. By way of example only, “C₁₋₄ alkyl”indicates that there are one to four carbon atoms in the alkyl chain,i.e. the alkyl chain is selected from the group consisting of methyl,ethyl, propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, or t-butyl.

Alkyl group may be optionally substituted, i.e. substituted orunsubstituted. When substituted, the substituted group(s) is(are)individually and independently selected from the group consisting ofcyclohydrocarbyl, aryl, heteroaryl, heteroalicyclyl, hydroxy, alkoxy,aryloxy, mercapto, allkylthio, arylthio, cyano, halo, carbonyl,thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl,C-amido, N-amido, S-sulfinamido, N-sulfinamido, C-carboxyl, O-carboxyl,isocyanato, thiocyano, isothiocyanato, nitro, silyl,trihalomethanesulfonyl, —NR′R″ or amino including mono- andbi-substituted amino group, and the protected derivatives thereof.Typical hydrocarbyl groups include, but are not limited to, methyl,ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl,ethenyl, propenyl, buenyl, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, and the like. Whenever a substituent is described as being“optionally substituted”, that substituent may be substituted with oneof the above substituents.

“C₁₋₄ alkyl” refers to an alkyl group as defined above containing one tofour carbon atoms. C₁₋₄ alkyl group may be optionally substituted asdefined for alkyl group.

“C₁₋₆ alkyl” refers to an alkyl group as defined above containing one tosix carbon atoms. C₁₋₆ alkyl group may be optionally substituted asdefined for alkyl group.

“C₁₋₁₂ alkyl” refers to an alkyl group as defined above containing oneto twelve carbon atoms. C₁₋₁₂ alkyl group may be optionally substitutedas defined for alkyl group.

“C₂₋₆ alkyl” refers to an alkyl group as defined above containing two tosix carbon atoms. C₂₋₆ alkyl group may be optionally substituted asdefined for alkyl group.

“C₃₋₆ alkyl” refers to an alkyl as defined above containing three to sixcarbon atoms. C₃₋₆ alkyl group may be optionally substituted as definedfor alkyl group.

“C₃₋₁₂ alkyl” refers to an alkyl as defined above containing three totwelve carbon atoms. C₃₋₁₂ alkyl group may be optionally substituted asdefined for alkyl group.

“C₆₋₁₂ alkyl” refers to an alkyl as defined above containing six totwelve carbon atoms. C₆₋₁₂ alkyl group may be optionally substituted asdefined for alkyl group.

“C₇₋₁₂ alkyl” refers to an alkyl as defined above containing seven totwelve carbon atoms. C₇₋₁₂ alkyl group may be optionally substituted asdefined for alkyl group.

In some embodiments, the alkyl group is C₁₋₁₂ alkyl.

In some embodiments, the alkyl group is C₁₋₈ alkyl.

In some embodiments, the alkyl group is C₁₋₆ alkyl.

In some embodiments, the alkyl group is C₁₋₄ alkyl.

“Alkoxy”, as used herein, refers to the formula —OR, wherein R is analkyl group defined as above, e.g. methoxy, ethoxy, n-propoxy, 1-methylethoxy(isopropoxy), n-butoxy, isobutoxy, sec-butoxy, t-butoxy, amoxy,t-amoxy, and the like.

In some embodiments, the alkoxy group is C₁₋₁₂ alkoxy.

In some embodiments, the alkoxy group is C₁₋₈ alkoxy.

In some embodiments, the alkoxy group is C₁₋₆ alkoxy.

In some embodiments, the alkoxy group is C₁₋₄ alkoxy.

“Alkylene”, as used herein, refers to a straight or branched divalenthydrocarbon chain group consisting solely of carbon and hydrogen andhaving from one to eight carbon atoms, which is linked with the othermoiety of the molecule and a residual group, e.g. methylene, ethylene,propylene, n-butylene. Alkylene chain can be linked with the othermoiety of the molecule and the residual group via one carbon atom in thechain or any two carbon atoms in the chain.

In some embodiments, the alkylene group is C₁₋₁₂ alkylene.

In some embodiments, the alkylene group is C₁₋₈ alkylene.

In some embodiments, the alkylene group is C₁₋₆ alkylene.

In some embodiments, the alkylene group is C₁₋₄ alkylene.

“Alkyleneoxy”, as used herein, refers to the formula —OR, wherein R isan alkylene group defined as above, e.g. methyleneoxy, ethyleneoxy,n-propyleneoxy, isopropyleneoxy, n-butyleneoxy, isobutyleneoxy,sec-butyleneoxy, t-butyleneoxy, amyleneoxy, t-amyleneoxy, and the like.

In some embodiments, the alkyleneoxy group is O(C₁₋₁₂)alkylene.

In some embodiments, the alkyleneoxy group is O(C₁₋₈)alkylene.

In some embodiments, the alkyleneoxy group is O(C₁₋₆)alkylene.

In some embodiments, the alkyleneoxy group is O(C₁₋₄)alkylene.

“Aryl”, as used herein, refers to a carbocycle (full carbon) or two ormore fused rings (rings sharing with two adjacent carbon atoms), havingcompletely delocalized π electron system. Examples of aryl groupinclude, but are not limited to, fluorenyl, phenyl and naphthyl. Thearyl group may have, for example, five to twelve carbon atoms. The arylgroup of the present application may be substituted or unsubstituted.Where substituted, hydrogen atom(s) is(are) substituted with one or moresubstituents independently selected from the group consisting of alkyl,cyclohydrocarbyl, aryl, heteroaryl, heteroalicyclyl, hydroxy, protectedhydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo,carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl,N-thiocarbamyl, C-amido, N-amido, S-sulfinamido, N-sulfinamido,C-carboxyl, protected C-carboxyl, O-carboxyl, isocyanato, thiocyano,isothiocyanato, nitro, silyl, trihalomethanesulfonyl, —NR′R″ (R′ and R″are alkyl groups defined herein) and protected amino.

In some embodiments, the aryl group is C₆-C₁₈ aryl.

In some embodiments, the aryl group is C₆-C₁₂ aryl.

In some embodiments, the aryl group is C₆-C₁₀ aryl.

“Heteroaryl (aromatic heterocyclyl)” refers to a five- toeighteen-membered aromatic ring group, containing one to seventeencarbon atoms and one to ten heteroatoms selected from the groupconsisting of nitrogen, oxygen and sulphur. For the purpose of thepresent invention, the heteroaryl may be monocyclic, bicyclic, tricyclicor tetracyclic ring system, which may comprise fused or bridged ringsystem. Moreover, nitrogen, carbon or sulphur atom in the heteroarylgroup may be optionally oxidized, and the nitrogen atom may beoptionally quaternized. The examples include, but are not limited to,azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzoindolyl,benzodioxolanyl, benzofuranyl, benzoxazolyl, benzothiazolyl,benzothiadiazolyl, benzo[b][1,4]dioxepanyl, 1,4-benzodioxanyl,benzonaphthofuranyl, benzodioxolanyl, benzodioxadienyl, benzopyranyl,benzopyronyl, benzofuranyl, benzofuranonyl, benzothienyl,benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridyl, carbazolyl, cinnolinyl,dibenzofuranyl, dibenzothienyl, furanyl, furanonyl, isothiazolyl,imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl,isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyl,naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl,1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl,2,3-naphthyridinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl,pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl,quinoxalinyl, quinolyl, quinuclidinyl, isoquinolyl, tetrahydroquinolyl,thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl andthiophenyl. Unless stated otherwise specifically in the specification,the term “heteroaryl” is meant to include the heteroaryl groups whichmay be optionally substituted with one or more substituentsindependently selected from the group consisting of alkyl,cyclohydrocarbyl, aryl, heteroaryl, heteroalicyclyl, hydroxy, protectedhydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo,carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl,N-thiocarbamyl, C-amido, N-amido, S-sulfinamido, N-sulfinamido,C-carboxyl, protected C-carboxyl, O-carboxyl, isocyanato, thiocyano,isothiocyanato, nitro, silyl, trihalomethanesulfonyl, —NR′R″ (R′ and R″are alkyl groups defined herein) and protected amino.

In some embodiments, the heteroaryl group is C₅₋₁₈ heteroaryl.

In some embodiments, the heteroaryl group is C₅₋₁₂ heteroaryl.

In some embodiments, the heteroaryl group is C₅₋₁₀ heteroaryl.

The term “heterocyclyl”, as used herein, refers to a stable three- totwelve-membered non-aromatic ring group which consists of carbon atomsand from one to five heteroatoms selected from the group consisting ofnitrogen, oxygen and sulphur. Examples of such heteroyclyl groupsinclude, but are not limited to, dioxolanyl, decahydroisoquinolyl,imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl,morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl,2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidyl,piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, thiazolidinyl,tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl,thiamorpholinyl, 1-oxo-thiomorpholinyl and 1,1-dioxo-thiomorpholinyl.Unless stated otherwise specifically in the specification, the term“heterocyclyl” is meant to include the heterocyclyl groups as definedabove, which may be optionally substituted with one or more substituentsselected from the group consisting of cyclohydrocarbyl, aryl,heteroaryl, heteroalicyclyl, hydroxy, alkoxy, aryloxy, mercapto,alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl,N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido,S-sulfinamido, N-sulfinamido, C-carboxyl, O-carboxyl, isocyanato,thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl,—NR′R″ (R′ and R″ are alkyl groups as defined in the presentapplication) or amino including mono- and di-substituted amino group,and the protected derivatives thereof.

In some embodiments, the heterocyclyl group is C₃₋₁₈ heterocyclyl.

In some embodiments, the heterocyclyl group is C₃₋₁₂ heterocyclyl.

In some embodiments, the heterocyclyl group is C₃₋₁₀ heterocyclyl.

“Sulfonyl” refers to —S(═O)₂R group, in which R may be alkyl,cyclohydrocarbyl, heterocyclyl, aryl, heteroaryl, etc, as defined above.The examples of sulfonyl groups include, but are not limited to,—S(═O)₂CH₃ (mesyl), —S(═O)₂CF₃, —S(═O)₂CH₂CH₃ and4-methylbenzenesulfonyl(tosyl).

“Optional” or “optionally” means that the subsequently describedcircumstances may or may not occur, and that the specification includesinstances where said event or circumstance occurs and instances in whichit does not. For example, “optionally substituted aryl” means that thearyl group may or may not be substituted and that the specificationincludes the substituted aryl group and the aryl group which is notsubstituted.

“Pharmaceutically acceptable carriers” include without limitation to anyadjuvant, carrier, excipient, glidant, sweetening agent, diluent,preservative, dye/colorant, flavor enhancer, surfactant, wetting agent,dispersing agent, suspending agent, stabilizer, isosmotic agent,solvent, or emulsifier, etc, which have been approved by the UnitedStates Food and Drug Administration as being acceptable for use inhumans or animals and have no side effects for constituting apharmaceutical composition.

“Pharmaceutically acceptable salts” include both “pharmaceuticallyacceptable acid addition salts” and “pharmaceutically acceptable baseaddition salts”.

“Pharmaceutically acceptable acid addition salt” refers to those saltswhich retain the biological effectiveness and properties of free bases,which are biologically or otherwise desirable, and which are formed withinorganic acids such as, but not limited to hydrochloric acid,hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and thelike; and organic acids such as, but not limited to, acetic acid,2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid,aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoicacid, camphanic acid, camphor-10-sulfonic acid, capric acid, caproicacid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamicacid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonicacid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid,galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid,glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid,glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid,lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid,malonic acid, mandelic acid, methanesulfonic acid, mucic acid,naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid,1-hydroxy-2-naphthoic acid, nicotinic acid, oleinic acid, orotic acid,oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamicacid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid,stearic acid, succinic acid, tartaric acid, thiocyanic acid,p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid and thelike.

“Pharmaceutically acceptable base addition salt” refers to those saltswhich retain the biological effectiveness and properties of the freeacids, which are biologically or otherwise desirable. These salts areprepared from addition of an inorganic base or an organic base into thefree acid. Salts derived from inorganic bases include, but are notlimited to, sodium, potassium, lithium, ammonium, calcium, magnesium,iron, zinc, copper, manganese, aluminum slats, and the like. Preferredinorganic salts are the ammonium, sodium, potassium, calcium, andmagnesium salts. Salts derived from organic bases include, but are notlimited to, slats of primary, secondary and tertiary amines, substitutedamines including naturally occurring substituted amines, cyclic aminesand basic ion exchange resins, such as ammonia, isopropylamine,trimethylamine, diethylamine, triethylamine, tripropylamine,diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol,2-diethylaminethanol, dicyclohexylamine, lysine, arginine, histidine,caffeine, procaine, hydrabamine, choline, betaine, benzylamine,phenylethylenediamine, ethylenediamine, glucosamine, methylglucosamine,theobromine, triethanolamine, trometamol, purine, piperazine,piperidine, N-ethyl piperidine, polyamine resin and the like.Particularly preferred organic bases are isopropylamine, diethylamine,ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.

“Pharmaceutical composition” refers to a formulation formed with acompound of the invention and a medium generally acceptable in the artfor the delivery of the biologically active compound to a mammal e.g.humans. Such a medium includes all pharmaceutically acceptable carriers,diluents or excipients.

“Therapeutically effective amount” refers to an amount of a compound ofthe invention which, when administered to a mammal, preferably a human,is sufficient to effect treatment (as defined below) of the tumor and/orcancer in the mammal, preferably a human. The amount of a compound ofthe invention which constitutes a “therapeutically effective amount”will vary depending on the compound, the condition and its severity, andthe age of the mammal to be treated, but can be determined routinely byone of ordinary skill in the art having regard to his own knowledge andto this disclosure.

“Treating” or “treatment”, as used herein, covers the treatment ofrelevant disease or condition in a mammal, preferably a human, havingthe relevant disease or disorder, and includes:

(i) preventing the disease or condition from occurring in a mammal, inparticular, when such mammal is predisposed to the condition but has notyet been diagnosed as having it;

(ii) inhibiting the disease or condition, i.e. arresting itsdevelopment; or

(iii) relieving the disease or condition, i.e. causing regression of thedisease or condition.

Throughout the treatment course, the administration in vivo can becarried out by means of a single administration, a continuousadministration or an intermittent administration (such as theadministration is carried out by divided dose at appropriate intervals).The method for determining the most effective administration mode anddose would have been well-known for one of ordinary skill in the art,and vary depending on the formulation to be used in the treatment, theobject of the treatment, the targeted cell to be treated and the subjectto be treated. A single or a multiple administration can be carried out,and the level of dose and the mode can be selected by an attendingdoctor.

Specific Embodiments

In one aspect, the present application relates to a compound representedby formula (I) and a pharmaceutically acceptable salt thereof,

wherein:

R¹ is selected from the group consisting of H, optionally substitutedalkyl, and optionally substituted alkoxy;

R² is selected from the group consisting of H, optionally substitutedaryl, optionally substituted heteroaryl, optionally substituted(alkyleneoxy)_(m)alkyl, optionally substituted heterocyclyl, optionallysubstituted alkyl, and optionally substituted sulfonyl;

R³ is selected from the group consisting of H, optionally substitutedaryl, optionally substituted heteroaryl, optionally substituted(alkyleneoxy)_(m)alkyl, optionally substituted heterocyclyl, optionallysubstituted alkyl, and optionally substituted sulfonyl;

or NR²R³ represents optionally substituted heterocyclyl;

m is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9,10, and 11;

W is selected from the group consisting of O and NH;

R⁴ is selected from the group consisting of H, F, and optionallysubstituted alkyl;

R⁵ is selected from the group consisting of H, F, optionally substitutedalkyl and OR⁶, wherein R⁶ is selected from the group consisting of H andtetrahydropyran-2-yl; and

n is selected from the group consisting of 1, 2 and 3.

In another aspect, the present application relates to a compoundrepresented by formula (I) and a pharmaceutically acceptable saltthereof,

wherein:

R¹ is selected from the group consisting of H, C₁₋₄alkyl, andC₁₋₄alkoxy;

R² is selected from the group consisting of H, aryl, heteroaryl,(C₁₋₄alkyleneoxy)_(m)C₁₋₄ alkyl, heterocyclyl, C₁₋₄ alkyl, and sulfonyl;

R³ is selected from the group consisting of H, aryl, heteroaryl, (C₁₋₄alkyleneoxy)_(m)C₁₋₄ alkyl, heterocyclyl, C₁₋₄ alkyl, and sulfonyl;

or NR²R³ represents heterocyclyl;

m is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9,10, and 11;

W is selected from the group consisting of O and NH;

R⁴ is selected from the group consisting of H, F and C₁₋₄alkyl;

R⁵ is selected from the group consisting of H, F, C₁₋₄alkyl and OR⁶,wherein R⁶ is selected from the group consisting of H andtetrahydropyran-2-yl; and

n is selected from the group consisting of 1, 2 and 3.

In some embodiments, R¹ in the compound represented by formula (I) isselected from the group consisting of H and OCH₃.

In some embodiments, W in the compound represented by formula (I) is O.

In some embodiments, R⁴ in the compound represented by formula (I) isCH₃.

In some embodiments, R⁵ in the compound represented by formula (I) isselected from the group consisting of OH and (tetrahydropyran-2-yl)oxy.

In some embodiments, R² in the compound represented by formula (I) isselected from the group consisting of H, methyl, ethyl,(morpholinylmethyl)phenyl, 4-((morpholin-1-yl)methyl)phenyl,(dimethylaminomethyl)phenyl, 4-((dimethylamino)methyl)phenyl,2-(2-(dimethylamino)ethoxy)ethyl, morpholin-1-yl, piperidin-1-yl,tetrahydropyrrol-1-yl, 4-(2-hydroxyethyl)piperazin-1-yl,(4-methylpiperazin)-1-yl, (4-ethylpiperazin)-1-yl,2-(tetrahydropyrrol-1-yl)ethyl, 3-(tetrahydropyrrol-1-yl)propyl,(2-(morpholin-1-yl)pyridin)-4-yl, (2-(morpholin-1-yl)pyridin)-5-yl,pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, (pyridin-4-yl)methyl,(pyridin-3-yl)methyl, (pyridin-2-yl)methyl, 2-(pyridin-4-yl)ethyl,2-(pyridin-3-yl)ethyl, 2-(pyridin-2-yl)ethyl, 2-(pyridin-4-yl)propyl,2-(pyridin-3-yl)propyl, 2-(pyridin-2-yl)propyl,2-((4-sulfamido)phenyl)ethyl, (3-(dimethylamino)propyl)piperazin-1-yl,3-((4-sulfamido)phenyl)propyl, 3-((4-methyl)piperazin-1-yl)propyl,3-((4-ethyl)piperazin-1-yl)propyl, 3-((4-propyl)piperazin-1-yl)propyl,2-((4-methyl)piperazin-1-yl)ethyl, 2-((4-ethyl)piperazin-1-yl)ethyl,2-((4-propyl)piperazin-1-yl)ethyl, 2-(dimethylamino)ethyl,2-(diethylamino)ethyl₂, 2-(dipropylamino)ethyl, 2-(piperidin-1-yl)ethyl,2-(morpholin-1-yl)ethyl, 2-(tetrahydropyrrol-1-yl)ethyl,3-(dimethylamino)propyl, 3-(diethylamino)propyl,3-(dipropylamino)propyl, 3-(piperidin-1-yl)propyl,3-(morpholin-1-yl)propyl, 3-(tetrahydropyrrol-1-yl)propyl,4-(dimethylamino)butyl, 4-(diethylamino)butyl, 4-(dipropylamino)butyl,4-(piperidin-1-yl)butyl, 4-(morpholin-1-yl)butyl,4-(tetrahydropyrrol-1-yl)butyl,2-(2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(diethylamino)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(dipropylamino)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(piperidin-1-yl)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(morpholin-1-yl)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(tetrahydropyrrol-1-yl)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethyl,2-(2-(2-(diethylamino)ethoxy)ethoxy)ethyl,2-(2-(2-(dipropylamino)ethoxy)ethoxy)ethyl,2-(2-(2-(piperidin-1-yl)ethoxy)ethoxy)ethyl,2-(2-(2-(morpholin-1-yl)ethoxy)ethoxy)ethyl,2-(2-(2-(tetrahydropyrrol-1-yl)ethoxy)ethoxy)ethyl, 6-purinyl, mesyl,benzenesulfonyl, pyrazin-2-yl, pyrimidin-2-yl, 2-hydroxyethyl,2-(2-hydroxyethoxyl)ethyl,2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxyl)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxyl)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxyl)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-methoxyl)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,and 2-(2-(2-(2-hydroxyethoxyl)ethoxy)ethoxy)ethyl.

In some embodiments, R³ in the compound represented by formula (I) isselected from the group consisting of H, methyl, ethyl,(morpholinylmethyl)phenyl, 4-((morpholin-1-yl)methyl)phenyl,(dimethylaminomethyl)phenyl, 4-((dimethylamino)methyl)phenyl,2-(2-(dimethylamino)ethoxy)ethyl, morpholin-1-yl, piperidin-1-yl,tetrahydropyrrol-1-yl, 4-(2-hydroxyethyl)piperazin-1-yl,(4-methylpiperazin)-1-yl, (4-ethylpiperazin)-1-yl,2-(tetrahydropyrrol-1-yl)ethyl, 3-(tetrahydropyrrol-1-yl)propyl,(2-(morpholin-1-yl)pyridin)-4-yl, (2-(morpholin-1-yl)pyridin)-5-yl,pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, (pyridin-4-yl)methyl,(pyridin-3-yl)methyl, (pyridin-2-yl)methyl, 2-(pyridin-4-yl)ethyl,2-(pyridin-3-yl)ethyl, 2-(pyridin-2-yl)ethyl, 2-(pyridin-4-yl)propyl,2-(pyridin-3-yl)propyl, 2-(pyridin-2-yl)propyl,2-((4-sulfamido)phenyl)ethyl, (3-(dimethylamino)propyl)piperazin-1-yl,3-((4-sulfamido)phenyl)propyl, 3-((4-methyl)piperazin-1-yl)propyl,3-((4-ethyl)piperazin-1-yl)propyl, 3-((4-propyl)piperazin-1-yl)propyl,2-((4-methyl)piperazin-1-yl)ethyl, 2-((4-ethyl)piperazin-1-yl)ethyl,2-((4-propyl)piperazin-1-yl)ethyl, 2-(dimethylamino)ethyl,2-(diethylamino)ethyl₂, 2-(dipropylamino)ethyl, 2-(piperidin-1-yl)ethyl,2-(morpholin-1-yl)ethyl, 2-(tetrahydropyrrol-1-yl)ethyl,3-(dimethylamino)propyl, 3-(diethylamino)propyl,3-(dipropylamino)propyl, 3-(piperidin-1-yl)propyl,3-(morpholin-1-yl)propyl, 3-(tetrahydropyrrol-1-yl)propyl,4-(dimethylamino)butyl, 4-(diethylamino)butyl, 4-(dipropylamino)butyl,4-(piperidin-1-yl)butyl, 4-(morpholin-1-yl)butyl,4-(tetrahydropyrrol-1-yl)butyl,2-(2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(diethylamino)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(dipropylamino)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(piperidin-1-yl)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(morpholin-1-yl)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(tetrahydropyrrol-1-yl)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethyl,2-(2-(2-(diethylamino)ethoxy)ethoxy)ethyl,2-(2-(2-(dipropylamino)ethoxy)ethoxy)ethyl,2-(2-(2-(piperidin-1-yl)ethoxy)ethoxy)ethyl,2-(2-(2-(morpholin-1-yl)ethoxy)ethoxy)ethyl,2-(2-(2-(tetrahydropyrrol-1-yl)ethoxy)ethoxy)ethyl, 6-purinyl, mesyl,benzenesulfonyl, pyrazin-2-yl, pyrimidin-2-yl, 2-hydroxyethyl,2-(2-hydroxyethoxyl)ethyl,2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxyl)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxyl)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxyl)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-methoxyl)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,and 2-(2-(2-(2-hydroxyethoxyl)ethoxy)ethoxy)ethyl.

In some embodiments, NR²R³ in the compound represented by formula (I) isselected from the group consisting of piperidin-1-yl, morpholin-1-yl,tetrahydropyrrol-1-yl, (4-(2-hydroxyethyl))piperazin-1-yl,(4-methyl)piperazin-1-yl, (4-ethyl)piperazin-1-yl,(4-propyl)piperazin-1-yl, 4-(3-hydroxypropyl)piperazin-1-yl,3-(morpholin-1-yl)propyl, adenin-1-yl,(4-(3-(dimethylamino)propyl)piperazin)-1-yl,(4-(2-(dimethylamino)ethyl)piperazin)-1-yl,(4-(3-(diethylamino)propyl)piperazin)-1-yl,(4-(2-(diethylamino)ethyl)piperazin)-1-yl,(4-(2-(piperidin-1-yl)ethyl)piperazin)-1-yl,(4-(3-(piperidin-1-yl)propyl)piperazin)-1-yl,(4-(2-(morpholin-1-yl)ethyl)piperazin)-1-yl,(4-(3-(morpholin-1-yl)propyl)piperazin)-1-yl,(4-(2-(tetrahydropyrrol-1-yl)ethyl)piperazin)-1-yl, and(4-(3-(tetrahydropyrrol-1-yl)propyl)piperazin)-1-yl.

In still another aspect, the present application relates to compoundsselected from the group consisting of:

No. n NR²R³  1 3

 2 2

 3 3

 4 2

 5 3

 6 2

 7 3

 8 2

 9 3

10 2

11 3

12 2

13 3

14 2

15 3

16 2

17 3

18 2

19 3

20 2

21 3

22 2

23 3

24 2

25 3

26 2

27 3

28 2

29 3

30 2

31 3

32 2

33 3

34 2

35 3

36 2

37 3

38 2

39 3

40 2

41 3

42 2

43 3

44 2

45 3

46 2

47 3

48 2

49 3

50 2

51 3

52 2

53 3

54 2

55 3

56 2

57 3

58 2

59 3

60 2

61 3

62 2

63 3

64 2

65 3

66 2 NH₂ 67 3 NH₂ 68 2 NHCH₃ 69 3 NHCH₃ 70 2 N(CH₃)₂ 71 3 N(CH₃)₂ 72 2

73 3

74 2

75 2

88 2

90 2

91 2

92 2

93 2

94 2

95 2

-   77)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((4-(2-hydroxyl)ethyl)piperazin-1-yl)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   78)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((3-(morpholin-1-yl)propyl)amino)-4-oxo-butyrato)-1-m    ethoxy-5,12-naphthalenedione acetate;-   79)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((4-methyl)piperazin-1-yl)amino)-4-oxo-butyrato)-1-me    thoxy-5,12-naphthalenedione acetate;-   80)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(4-ethylpiperazin-1-yl)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   81)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   82)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((pyridin-4-yl)methyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   83)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((pyridin-3-yl)methyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   84)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(pyridin-2-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   85)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(pyridin-3-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   86)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(pyridin-4-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   87)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(4-(3-(dimethylamino)propyl)piperazin-1-yl)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   89)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((2-(morpholin-1-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    acetate;-   96)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((2-(morpholin-1-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    phosphate; and-   99)    10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((2-(morpholin-1-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione    hydrochloride.

In yet still another aspect, the present application relates to aprocess for preparing a compound represented by formula (I), comprising:

reacting a compound represented by formula (II) with a compoundrepresented by formula (III) in the presence of a condensation agent toobtain the compound represented by formula (I),

wherein:

in the compound represented by formula (I),

R¹ is selected from the group consisting of H, C₁₋₄alkyl, andC₁₋₄alkoxy; R² is selected from the group consisting of H, aryl,heteroaryl, (C₁₋₄alkyleneoxy)_(m)C₁₋₄alkyl, heterocyclyl, C₁₋₄alkyl, andsulfonyl; R³ is selected from the group consisting of H, aryl,heteroaryl, (C₁₋₄ alkyleneoxy)_(m)C₁₋₄ alkyl, heterocyclyl, C₁₋₄ alkyl,and sulfonyl; or NR²R³ represents heterocyclyl; m is selected from thegroup consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11; W isselected from the group consisting of O and NH; R⁴ is selected from thegroup consisting of H, F and C₁₋₄alkyl; R⁵ is selected from the groupconsisting of H, F, C₁₋₄alkyl and OR⁶, in which R⁶ is selected from thegroup consisting of H and tetrahydropyran-2-yl; n is selected from thegroup consisting of 1, 2 and 3;

groups represented by R¹, W, R⁴, R⁵ in the compound represented byformula (II) are the same as groups represented by R¹, W, R⁴, R⁵ in thecompound represented by formula (I);

n in the compound represented by formula (III) has the same meanings asn in the compound represented by formula (I); groups represented by R⁷and R⁸ in the compound represented by formula (III) are the same asgroups represented by R² and R³ in the compound represented by formula(I), provided that groups represented by R⁷ and R⁸ do not comprise NH orNH₂; when groups represented by R⁷ and R⁸ comprise NH or NH₂, thecompound represented by formula (III) has an amino-protecting group atN-terminus, and is subject to a deprotection reaction to obtain thecompound represented by formula (I).

In some embodiments, the process for preparing a compound represented byformula (I) further comprises adding an activator.

Exemplary examples of activators that can be used in the process forpreparing a compound represented by formula (I) according to the presentapplication include, but are not limited to, N-hydroxysuccinimide(HOSu), 1-hydroxy-7-azobenzotriazole (HOAt), 1-hydroxybenzotriazole(HOBt), N-hydroxyphthalimide (NHPI), N-hydroxy-1,8-naphthalimide (NHNI),pentafluorophenol (PFPOH),2-(7-azobenzotriazole)-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HATU), benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HBTU), 6-chlorobenzotriazole-1,1,3,3-tetramethyluroniumhexafluorophosphate (HCTU),O-(7-azabenzotriazole-1-yl)-di(tetrahydropyrrolyl)carbeniumhexafluophosphate (HAPyU),O-(benzotriazole-1-yl)-di(tetrahydropyrrolyl)carbenium hexafluophosphate(HBPyU), O-benzotriazole-N,N,N′,N′-tetramethyluronium tetrafluoroborate(TBTU), 2-succinimido-1,1,3,3-tetramethyluronium tetrafluoroborate(TSTU), 2-(5-norbornen-2,3-dicarboximido)-1,1,3,3-tetramethyluroniumtetrafluoroborate quaternary ammoniumsalt (TNTU),benzotriazole-1-yloxytri(dimethylamino)phosphonium hexafluorophosphate(BOP), benzotriazol-1-yl-oxytripyrrolidino-phosphoniumhexafluorophosphate (PyBOP),(3H-1,2,3-triazolo[4,5-b]pyridin-3-oxy)tri-1-pyrrolidinylphosphoniumhexafluorophosphate (PyAOP), diphenylphosphinyl chloride (DPP-Cl),diphenyl phosphoryl azide (DPPA), cyanodiethylphosphate (DECP),bis(2-oxo-3-oxazolidinyl)phosphinyl chloride (BOP-Cl) and a mixturethereof.

Exemplary examples of condensation agents that can be used in theprocess for preparing a compound represented by formula (I) according tothe present application include, but are not limited to,dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC),1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI),2-(7-azobenzotriazole)-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HATU), benzotriazol-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HBTU), 6-chlorobenzotriazol-1,1,3,3-tetramethyluroniumhexafluorophosphate (HCTU),O-(7-azabenzotriazol-1-yl)-di(tetrahydropyrrolyl)carbeniumhexafluophosphate (HAPyU),O-(benzotriazol-1-yl)-di(tetrahydropyrrolyl)carbenium hexafluophosphate(HBPyU), O-benzotriazol-N,N,N′,N′-tetramethyluronium tetrafluoroborate(TBTU), 2-succinimido-1,1,3,3-tetramethyluronium tetrafluoroborate(TSTU), 2-(5-norbornen-2,3-dicarboximido)-1,1,3,3-tetramethyluroniumtetrafluoroborate quaternary ammonium salt (TNTU),benzotriazol-1-yloxytri(dimethylamino)phosphonium hexafluorophosphate(BOP), benzotriazol-1-yl-oxytripyrrolidino-phosphoniumhexafluorophosphate (PyBOP),(3H-1,2,3-triazolo[4,5-b]pyridin-3-oxy)tri-1-pyrrolidinylphosphoniumhexafluorophosphate (PyAOP), diphenylphosphinyl chloride (DPP-Cl),diphenyl phosphoryl azide (DPPA), cyanodiethylphosphate (DECP),bis(2-oxo-3-oxazolidinyl)phosphinyl chloride (BOP-Cl) and a mixturethereof.

In some embodiments, the process for preparing a compound represented byformula (I) further comprises adding a catalyst.

Exemplary examples of catalysts that can be used in the process forpreparing a compound represented by formula (I) according to the presentapplication include, but are not limited to, 4-dimethylaminopyridine,4-pyrrolidinylpyridine and a mixture thereof.

Exemplary examples of nitrogen-protecting groups that can be used in theprocess for preparing a compound represented by formula (I) according tothe present application include, but are not limited to, Fmoc(fluorenylmethoxycarbony), Boc (t-butyloxycarboryl), CBZ (carbobenzoxy),Tr (trityl) or Alloc (allyloxycarbonyl), Teoc(trimethylsilylethoxycarbonyl), methoxycarbonyl, ethoxycarbonyl, Pht(phthaloyl), Tos (tosyl), Ns (o/p-nitrobenzenesulfonyl), Tfa(trifluoroacetyl), pivaloyl, benzoyl, Trt (trityl), Dmb(2,4-dimethoxybenzyl), PMB (p-methoxybenzyl), and Bn (benzyl).

Exemplary examples of deprotection reactants that can be used in theprocess for preparing a compound represented by formula (I) according tothe present application include, but are not limited to, hydrogen gas,NH₃, aminoethanol, dimethylamine, diethylamine, piperidine, piperazine,DBU, hydrochloric acid, phosphoric acid, acetic acid, formic acid,trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid,p-toluenesulfonic acid and a mixture thereof.

In some embodiments, the compound represented by formula (III) in theprocess for preparing a compound represented by formula (I) is obtainedby a reaction of a compound represented by formula (IV) with HNR⁷R⁸,

wherein:

n in the compound represented by formula (IV) has the same meanings as nin the compound represented by formula (I);

groups represented by R² and R³ in HNR⁷R⁸ are the same as groupsrepresented by R² and R³ in the compound represented by formula (I).

In some embodiments, the process for preparing a compound represented byformula (III) further comprises adding an alkaline compound.

Exemplary examples of alkaline compounds that can be used in the processfor preparing a compound represented by formula (III) according to thepresent application include, but are not limited to, triethylamine,pyridine, diisopropylethylamine, trimethylamine, N-methylpyrrolidine,N-methylpiperidine, N-methylmorpholine, N-ethylpyrrolidine,N-ethylpiperidine, N-ethylmorpholine and a mixture thereof.

In yet another aspect, the present application relates to apharmaceutical composition comprising a compound represented by formula(I) or a pharmaceutically acceptable salt thereof, and apharmaceutically acceptable carrier,

wherein:

R¹ is selected from the group consisting of H, C₁₋₄alkyl, andC₁₋₄alkoxy;

R² is selected from the group consisting of H, aryl, heteroaryl, (C₁₋₄alkyleneoxy)_(m)C₁₋₄alkyl, heterocyclyl, C₁₋₄ alkyl, and sulfonyl;

R³ is selected from the group consisting of H, aryl, heteroaryl,(C₁₋₄alkyleneoxy)_(m)C₁₋₄ alkyl, heterocyclyl, C₁₋₄alkyl, and sulfonyl;

or NR²R³ represents heterocyclyl;

m is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9,10, and 11;

W is selected from the group consisting of O and NH;

R⁴ is selected from the group consisting of H, F and C₁₋₄alkyl;

R⁵ is selected from the group consisting of H, F, C₁₋₄alkyl and OR⁶,wherein R⁶ is selected from the group consisting of H andtetrahydropyran-2-yl; and

n is selected from the group consisting of 1, 2 and 3.

In another aspect, the present application relates to a formulationcomprising a compound represented by formula (I) or a pharmaceuticallyacceptable salt thereof, and a pharmaceutically acceptable carrier,

wherein:

R¹ is selected from the group consisting of H, C₁₋₄alkyl, andC₁₋₄alkoxy;

R² is selected from the group consisting of H, aryl, heteroaryl, (C₁₋₄alkyleneoxy)_(m)C₁₋₄ alkyl, heterocyclyl, C₁₋₄ alkyl, and sulfonyl;

R³ is selected from the group consisting of H, aryl, heteroaryl, (C₁₋₄alkyleneoxy)_(m)C₁₋₄ alkyl, heterocyclyl, C₁₋₄ alkyl, and sulfonyl;

or NR²R³ represents heterocyclyl;

m is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9,10, and 11;

W is selected from the group consisting of O and NH;

R⁴ is selected from the group consisting of H, F and C₁₋₄alkyl;

R⁵ is selected from the group consisting of H, F, C₁₋₄alkyl and OR⁶,wherein R⁶ is selected from the group consisting of H andtetrahydropyran-2-yl; and

n is selected from the group consisting of 1, 2 and 3.

In some embodiments, the formulation comprising a compound representedby formula (I) or a pharmaceutically acceptable salt thereof and apharmaceutically acceptable carrier is a formulation for injection.

Exemplary examples that can be used in the formulation according to thepresent application include, but are not limited to, a conventionalpowder injection, a freeze-dried powder injection, a hydro-injection, anemulsion, a solution and a suspension.

In still another aspect, the present application relates to a method fortreating and/or preventing tumor and/or cancer, comprising administeringto a subject in need thereof a therapeutically effective amount of acompound represented by formula (I) or a pharmaceutically acceptablesalt thereof, or administering a therapeutically effective amount of apharmaceutical composition comprising a compound represented by formula(I) or a pharmaceutically acceptable salt and a pharmaceuticallyacceptable carrier, or administering a therapeutically effective amountof a formulation comprising a compound represented by formula (I) or apharmaceutically acceptable salt and a pharmaceutically acceptablecarrier,

wherein:

R¹ is selected from the group consisting of H, C₁₋₄alkyl, andC₁₋₄alkoxy;

R² is selected from the group consisting of H, aryl, heteroaryl, (C₁₋₄alkyleneoxy)_(m)C₁₋₄ alkyl, heterocyclyl, C₁₋₄ alkyl, and sulfonyl;

R³ is selected from the group consisting of H, aryl, heteroaryl,(C₁₋₄alkyleneoxy)_(m)C₁₋₄ alkyl, heterocyclyl, C₁₋₄ alkyl, and sulfonyl;

or NR²R³ represents heterocyclyl;

m is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9,10, and 11;

W is selected from the group consisting of O and NH;

R⁴ is selected from the group consisting of H, F and C₁₋₄alkyl;

R⁵ is selected from the group consisting of H, F, C₁₋₄alkyl and OR⁶,wherein R⁶ is selected from the group consisting of H andtetrahydropyran-2-yl; and

n is selected from the group consisting of 1, 2 and 3.

Exemplary examples of tumors and/or cancers that can be treated and/orprevented by the method according to the present application include,but are not limited to, liver cancer, gastric cancer, breast cancer,lung cancer, intestine cancer, ovarian cancer, pancreatic cancer, headand neck cancer, cervical cancer, renal cancer, melanoma, prostaticcancer, brain glioma, various leukemia, lymphoma, and multiple bonemarrow cancer.

The compound and a salt thereof according to the present applicationpossess good anticancer and/or antitumor activity, and good watersolubility and stability, as well as good tolerance in animal bodies.Therefore, they are prone to being developed as clinical drugs.

EXAMPLES

Although any one skilled in the art is capable of preparing thecompounds of the present application according to the general techniquesdisclosed herein above, more specific details on synthetic techniquesfor the compound of the present application are provided elsewhere inthis specification for conveniences. In addition, all reagents andreaction conditions employed in synthesis are known to those skilled inthe art and are available from ordinary commercial sources.

Abbreviations

Su: succinimide; Bt: benzotrazol-1-yl; At: 7-azobenzotrazol-1-yl; Fmoc:fluorenylmethoxycarbonyl; Boc: t-butoxycarbonyl; CBZ: carbobenzoxy; Tr:trimethylphenyl; Alloc: allyloxycarbonyl; DBU:1,8-diazacyclo[5,4,0]hendecene-7; DIEA: diisopropylethylamine; DMAP:4-dimethylaminopyridine; EDC.HCl:1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; HOAt:N-hydroxy-7-azobenzotriazole; DCC: dicyclohexylcarbodiimide; DIC:N,N-diisopropylcarbodiimide. NCI-H446: human small cell lung cancer cellline; BxPC-3: human pancreatic cancer cell line; SK-OV-3: human ovariancancer cell line; MDA-MB-453: human breast cancer cell line; 22Rv1:human prostate cancer cell line; A375: human cutaneous melanoma cellline; A431: human epidermal carcinoma cell line; MCF-7: human breastcancer cell line; NCI-446: human small cell lung cancer cell line;NCI-H460: human large cell lung cancer cell line; B16: mouse melanomacell line; 786-O: human kidney clear cell adenocarcinoma cell line;DU-145: prostate cancer cell line; Hep3B: liver cancer cell line;SK-Br-3: human breast cancer cell line; MTT: nitroblue tetrazolium;McCoy's 5A: McCoy's 5A Medium; FBS: fetal calf serum; PBS: phosphatebuffer, pH 7.4; EDTA: ethylenediamine tetraacetic acid; DMSO: dimethylsulfoxide; RPMI-1640: RPMI-1640 Medium; SRB: sulforhodamine; TCA:trichloroacetic acid; ddH₂O: double distilled water; Tris:trihydroxymethylaminomethane; L15: Leibovitz's L-15 Medium; compound A:3′-pyrrolyldoxorubicin-14-oxo-succinic acid monoester.

The numberings of the substituents in the present application areindicated as follows.

Preparation 1 3′-pyrrolyldoxobubicin10-((3′-(Pyrrol-1-YL)-2′,3′,6′-Trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-Tetrahydro-6,8,11-Trihydroxy-8-Hydroxyacetyl-1-Memthoxy-5,12-Naphthalenedione

To a three-neck flask (1 L) were added doxorubicin hydrochloride (3.076g), distilled water (300 mL) and 1,2-dichloroethane (300 mL),2,5-dimethoxytetrahydrofuran (30 mL) and glacial acetic acid (6 mL). Themixture was heated and refluxed for 45 min under the protection of argongas until the reaction was completed. The reaction was cooled to theroom temperature. The reaction solution was poured into ice water (200mL), and then stood to separate. The organic phase was washed withsaturated saline (200 mL) once, dried over anhydrous magnesium sulfate,filtered and rotary-evaporated to dryness. To the aqueous phase wasadded 5% sodium bicarbonate aqueous solution (100 mL) while beingstirred in an ice bath, and then extracted with chloroform (50 mL×3).The chloroform layers were combined and washed with saturated saline(100 mL) once, filtered and rotary-evaporated to remove the solvent. Theresultant crude was combined with the crude obtained above. Theresultant mixture was purified with column chromatography, eluting withchloroform: methanol=35:1, to give the product (2.91 g). MS: 592 (M-1)

Preparation 2 4-(4-nitrobenzyl)morpholine

To a reaction flask was added p-nitrobenzyl bromide (72.084 g).Dichloromethane (470 mL, dried via molecular sieve) was added todissolve p-nitrobenzyl bromide. Anhydrous potassium carbonate (91.909 g)was added. The mixture was cooled in an ice bath under the protection ofargon gas. After 20 min, to the reaction flask was dropwise addedmorpholine (over about 30 min). After the addition was completed, theice bath was removed. The resultant mixture was stirred overnight at theroom temperature. After the reaction was completed, water (150 mL) wasadded. The pH of the mixture was adjusted with 5% citric acid aqueoussolution to 4-5 under stirring. After standing to separate, the organicphase was washed with water (260 mL×1), dried over anhydrous MgSO₄ forhalf an hour, and then filtered. The filtrate was concentrated, anddried under reduced pressure by oil pump, to give the target compound(71.9 g, yield 97.16%).

Preparation 3 4-(morpholinylmethyl)aniline

To a reaction flask were added 4-(4-nitrobenzyl)morpholine (37.4 g) andabsolute ethanol (520 mL). The mixture was mechanically stirred, andthen acetic acid (34 mL) was added. The resultant mixture was warmed inan oil bath. The solution became clear at 40° C. To 1 N hydrochloricacid (HCl) (84 mL) was added iron powders (48.002 g), and stirred for 10min, filtered by suction. The filter cake was washed with absoluteethanol, and then added into the reaction flask. The mixture was warmedin an oil bath to reflux, and maintained under reflux until the reactionwas completed (about 3 hr). After the reaction was completed, thereaction solution was filtered by suction. The filtrate wasconcentrated, and then dissolved in ethyl acetate (400 mL) and water(400 mL). The mixture was mixed and then stood to separate. The organiclayer was discarded. The aqueous phase was washed with dichloromethane(100 mL×3). The pH was adjusted with NaOH solids to 9. Lots of brownsolids precipitated from the solution, The solids were filtered bysuction. The filter cake was washed with distilled water (20 mL×2) andthen discarded. The pH of the filtrate was adjusted with sodiumhydroxide (NaOH) to 13. The resultant solution was extracted withdichloromethane (100 mL×2). The organic phase was directly concentratedto give the target compound.

Preparation 4 5-(4-(morpholinylmethyl)phenylamino)-5-oxopentanoic acid

To a reaction flask was added 4-(morpholinylmethyl)aniline (960 mg).Dichloromethane (7.6 mL, dried via molecular sieve) was added todissolve 4-(morpholinylmethyl)aniline. The solution was stirred underthe protection of argon gas. To the reaction flask were added glutaricanhydride (741 mg), DIEA (1.1 mL) and DMAP (62 mg). The mixture wasstirred overnight at the room temperature. After the reaction wascompleted, dichloromethane (50 mL) and distilled water (30 mL) wereadded. The pH of the resultant mixture was adjusted with NaOH solids to13. The resultant solution was mixed homogeneously again, and stood toseparate. The pH of the aqueous phase was adjusted with HCl to 3. Thesolution was frozen to dry. The resultant solids were washed withabsolute ethanol (50 mL) and filtered. The resultant filtrate wasconcentrated and redissolved in dichloromethane. The resultant solutionwas concentrated again to remove the residual absolute ethanol. Theresultant product was directly dried under reduced pressure to give thetarget compound.

Preparation 5 N,N-dimethyl(4-nitrophenyl)methylamine

To a reaction flask were added nitrobenzyl bromide (6.291 g) anddichloromethane (50 mL). Anhydrous potassium carbonate (12.423 g) anddimethylamine hydrochloride (4.891 g) were successively added to thereaction flask. The mixture was stirred overnight at the roomtemperature. After the reaction was completed, the reaction solution wasfiltered by suction. The filter cake was washed with dichloromethane (10mL). The filtrate was washed three times with distilled water (50 mL×1,30 mL×2). The organic phase was directly concentrated and dried underreduced pressure by oil pump to give an oil (4.553 g).

Preparation 6 4-((dimethylamino)methyl)aniline

To a reaction flask was added N,N-dimethyl(4-nitrophenyl)methyamine(4.553 g). Anhydrous ethanol was added to dissolveN,N-dimethyl(4-nitrophenyl)methyamine. After adding acetic acid (5.2mL), the mixture was mechanically stirred. To 1 N HCl (40 mL) was addediron powders (11.339 g). The iron powders were immersed for 10 min andfiltered by suction. The filter cake was washed with absolute ethanoland then added into the reaction flask. The mixture was warmed in an oilbath to reflux, and maintained under reflux until the reaction wascompleted (about 35 min). After the reaction was completed, the reactionsolution was filtered by suction. The filter cake was washed withabsolute ethanol. The filtrate was concentrated and then added intodistilled water (100 mL). The pH of the mixture was adjusted with NaOHto 14. Lots of solids were precipitated. The solids were filtered bysuction. The filtrate was extracted with dichloromethane (100 mL×1), andthe aqueous phase was discarded. To the organic phase was addeddistilled water (60 mL). The pH was adjusted with 2 N HCl to 2. Theresultant product was mixed and stood to separate. The organic phase wasdiscarded. The pH of the aqueous phase was adjusted with NaOH to 7. Themixture was extracted with dichloromethane (40 mL×2) and the aqueousphase was discarded. The organic phase was washed with distilled water(40 mL×1) once and the aqueous phase was discarded. The organic phasewas directly concentrated to give the target compound.

Preparation 7 T-butyl 2-(2-hydroxyethoxy)ethylcarbamate

To a single-neck flask was added 2-(2-aminoethoxyl)ethanol (10.500 g).Tetrahydrofuran (25 mL) was added to dissolve 2-(2-aminoethoxyl)ethanol.Anhydrous sodium carbonate (5.300 g) was dissolved in distilled water(30 mL). The solution was added into the single-neck flask and cooled inan ice bath. Di-t-butyl dicarbonate (28.340 g) was dissolved intetrahydrofuran (70 mL). The resultant solution was slowly dropwiseadded in the reaction system (for about 1 hr). After the addition, themixture was stirred for 1.5 hr. After the reaction was completed, thereaction solution was filtered by suction. The filter cake was washedwith tetrahydrofuran twice and then discarded. The filtrate wasconcentrated, then dissolved in ethyl acetate (150 mL) and distilledwater (100 mL). The solution was mixed and then stood to separate. Theaqueous phase was washed again with ethyl acetate (100 mL×2) twice. Allthe organic phases were combined, dried over MgSO₄, filtered andconcentrated to give the target compound.

Preparation 82-(2-T-butoxycarbonylamino)ethoxy)ethyl-4-methylbenzenesulfonate

To a single-neck flask (250 mL) were added t-butyl2-(2-hydroxyethoxyl)ethylcarbamate (20.5 g) and p-toluenesulfonylchloride (28.575 g). Tetrahydrofuran (50 mL) was added to dissolve themixture. The resultant solution was cooled in an ice bath. Sodiumhydroxide (8.000 g) was dissolved in distilled water (32 g). Thesolution was dropwise added in the reaction flask. The mixture wasstirred overnight. After the reaction was completed, the reactionsolution was concentrated (to remove tetrahydrofuran). To the resultantproduct were added ethyl acetate (150 mL) and distilled water (100 mL).The solution was mixed homogeneously and stood to separate. The organicphase was washed with saturated NaCl once, dried over MgSO₄ for 30 min,filtered and concentrated to give an oil. After standing overnight,solids were precipitated. The solids were filtered by suction. Thefilter cake was eluted with ethyl acetate twice to give the targetcompound.

Preparation 9 T-Butyl 2-(2-(dimethylamino)ethoxy)ethylcarbamate

To a reaction flask was added dimethylamine hydrochloride (30.922 g).Distilled water (50 mL) was added to dissolve dimethylaminehydrochloride. The mixture was cooled in an ice bath. To the reactionflask was added 20% sodium hydroxide aqueous solution (76.885 g). Afterstirring for 20 min, 2-(2-t-butoxycarbonylamino)ethoxy)ethyl4-methylbenzenesulfonate (13.621 g) was dissolved in absolute ethanol(50 mL) and tetrahydrofuran (30 mL). To the reaction flask was added theresultant solution. The mixture reacted overnight. The reaction flaskwas moved to an oil bath at 40° C. The mixture was stirred for 2.5 hr.After the reaction was completed, the organic solvent was removed byconcentration. The crude product was extracted with ethyl acetate (150mL×1) once. The pH of the aqueous phase was adjusted with NaOH to 9. Theaqueous phase was extracted with ethyl acetate (100 mL×1) once. Theorganic phases were combined, dried over MgSO₄ for 30 min, then filteredand concentrated to give the target compound.

Preparation 10 2-(2-(dimethylamino)ethoxy)ethylamine

In a reaction flask t-butyl 2-(2-(dimethylamino)ethoxy)ethylcarbamatewas dissolved in dichloromethane (70 mL). The mixture was cooled in anice bath under the protection of argon gas. To the reaction flask wasdropwise added trifluoroacetic acid (17 mL). The mixture reactedovernight. After the reaction was completed, the reaction solution wasextracted with distilled water (100 mL) once. The organic phase wasdiscarded. The pH of the aqueous phase was adjusted with NaOH to 13. Theaqueous phase was extracted with dichloromethane (150 mL×3) three times.The resultant organic phase was directly concentrated to give the targetcompound.

Preparation 11 T-butyl-di(2-hydroxyethyl)carbamate

To a reaction flask was added dihydroxyethylamine (31.5 g).Tetrahydrofuran (50 mL) and distilled water (50 mL) were added todissolve dihydroxyethylamine. Di-t-butyl dicarbonate (85.0 g) wasdissolved in tetrahydrofuran (80 mL). The resultant solution wasdropwise added into the reaction flask in an ice bath (over 2 hr). Afterthe addition was completed, the mixture was stirred until the reactionwas completed (for about 1.5 hr). The reaction solution wasconcentrated, then dissolved in dichloromethane (200 mL) and distilledwater (150 mL), mixed and stood to separate. The aqueous layer wasextracted with dichloromethane (100 mL×4) four times. All the organicphases were combined and concentrated to directly use in the subsequentreaction.

Preparation 12 T-butyl-di(2-p-toluenesulfonatoethyl)carbamate

To a reaction flask were added t-butyl-di(2-hydroxyethyl)carbamate (61.5g) and p-toluenesulfonyl chloride (137.2 g). Tetrahydrofuran (200 mL)was added to dissolve t-butyl-di(2-hydroxyethyl)carbamate andp-toluenesulfonyl chloride. The solution was cooled in an ice bath. 20%sodium hydroxide aqueous solution (216 g) was dropwise added into thereaction flask (over 70 min). The resultant mixture was stirredovernight in an ice bath. After the reaction was completed, the pH ofthe reaction solution was adjusted with 20% NaOH aqueous solution to 13.The solution was stirred for 2 hr in an oil bath at 40° C. The reactionsolution was concentrated. Dichloromethane (250 mL) was added todissolve the concentrated reaction solution. The resultant solution waswashed with distilled water (100 mL) once. The organic phase wasdirectly concentrated to give the crude target compound.

Preparation 13 T-Butyl di(2-(dimethylamino)ethyl)carbamate

To a reaction flask was added dimethylamine hydrochloride (116.1 g).Distilled water (60 mL) was added to dissolve dimethylaminehydrochloride. The solution was cooled in an ice bath. 20% sodiumhydroxide aqueous solution (284.8 g) was added into the reaction flask(over 70 min). After the addition was completed, the mixture was stirredfor 20 min. T-butyl-di(2-p-toluenesulfonatoethyl)carbamate (73.2 g) wasdissolved in tetrahydrofuran (200 mL). The resultant mixture was addedto the reaction flask and stirred in an oil bath at 40° C. until thereaction was completed. The reaction solution was concentrated andwashed with ethyl acetate (250 mL) once. The organic phase wasre-extracted with distilled water (150 mL×2) twice. All the aqueousphases were combined. The pH of the aqueous phase was adjusted with NaOHto 14. The resultant solution was extracted with dichloromethane (200mL×1, 150 mL×6) seven times. The seven fractions of dichloromethane werecombined, dried over anhydrous MgSO₄ for 30 min, filtered andconcentrated. The resultant crude product was purified by columnchromatography (developing solvent was CHCl₃:CH₃OH=15:1) to give thetarget compound.

Preparation 14 Di(2-(dimethylamino)ethyly)amine

To a reaction flask were addedt-butyl-di(2-(dimethylamino)ethyl)carbamate (3.000 g) andtetrahydrofuran (20 mL). The mixture was cooled in an ice bath. To thereaction flask was dropwise added concentrated hydrochloric acid (9.6mL) (over 15 min). The mixture was stirred in an ice bath until thereaction was completed. After the reaction solution was concentrated toremove tetrahydrofuran, the resultant solution was washed withdichloromethane (50 mL) once. The organic phase was discarded. The pH ofthe aqueous phase was adjusted with K₂CO₃ to 10. The aqueous solutionwas extracted with dichloromethane (50 mL×4) four times. The fourfractions of dichloromethane were combined, dried over anhydrous MgSO₄for 30 min, filtered and concentrated to give the target compound.

Preparation 15 2-(2-(2-(2-T-butoxyethoxy)ethoxy)ethoxy)ethanol

To a reaction flask which was pre-protected with argon gas were addedtetraethylene glycol (191.2 mL) and DIEA (300 mL). Dichloromethane (80mL, dried via molecular sieves) was added to the reaction flask. Themixture was dissolved with stirring at the room temperature, and thencooled in an ice bath. Triphenylchloromethane (205.9 g) was dissolved indichloromethane (400 mL, dried via molecular sieves) (over 4 hr). Theresultant mixture was added to the reaction flask and reacted overnight.After the reaction was completed, the reaction solution was successivelywashed with 5% citric acid aqueous solution (500 mL×4) four times andwith NaCl aqueous solution (250 mL×1) once, dried over anhydrous MgSO₄for 30 min, filtered and concentrated to give the target compound.

Preparation 162-(2-(2-(2-T-butoxyethoxy)ethoxy)ethoxy)ethyl-4-methylbenzenesulfonate

To a reaction flask were added2-(2-(2-(2-t-butoxyethoxy)ethoxy)ethoxy)ethanol (347.5 g) andp-toluenesulfonyl chloride (227.7 g). Tetrahydrofuran (200 mL) was addedto dissolve 2-(2-(2-(2-t-butoxyethoxy)ethoxy)ethoxy)ethanol andp-toluenesulfonyl chloride. To the reaction flask was added 20% sodiumhydroxide aqueous solution (318.8 g) in an ice bath (over 2 hr). Themixture reacted overnight. After the reaction was completed, thereaction solution was concentrated to remove tetrahydrofuran. To theresultant crude product were added ethyl acetate (300 mL) and distilledwater (50 mL). The solution was mixed homogeneously and stood toseparate. The organic phase was washed with saturated NaCl aqueoussolution (200 mL) once, dried over anhydrous MgSO₄ for 30 min, filteredand concentrated to give the target compound.

Preparation 172-(2-(2-(2-(2-T-butoxyethoxy)ethoxy)ethoxy)ethyl)isoindol-1,3-dione

To a reaction flask were added2-(2-(2-(2-t-butoxyethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate(373.7 g) and potassium phthalimide (175.7 g). DMF (350 mL, dried overmolecular sieves) was added to dissolve the mixture. The resultantsolution was warmed and maintained at 65° C. in an oil bath until thereaction was completed (for about 8 hr). After the reaction solution wasconcentrated, ethyl acetate (250 mL) and distilled water (200 mL) wereadded. The resultant solution was mixed homogeneously and stood toseparate. The organic phase was washed with saturated NaCl aqueoussolution (150 mL) once, dried over anhydrous MgSO₄ for 30 min, filteredand concentrated to give a crude product. The crude product wasre-crystallized from anhydrous ethanol to give the target compound.

Preparation 18 2-(2-(2-(2-t-butoxyethoxy)ethoxy)ethoxy)ethylamine

To a reaction flask was added2-(2-(2-(2-(2-t-butoxyethoxy)ethoxy)ethoxy)ethyl)isoindol-1,3-dione(193.515 g). Tetrahydrofuran (350 mL) was added to dissolve2-(2-(2-(2-(2-t-butoxyethoxy)ethoxy)ethoxy)ethyl)isoindol-1,3-dione.After 25% methylamine aqueous solution (127.410 g) was added, theresultant solution became clear by mechanically stirring at the roomtemperature. The mixture reacted overnight. After the reaction wasstirred for 30 min in an oil bath at 40° C., the reaction solution wasconcentrated to give white solids. These solids were dissolved in ethylacetate (300 mL) and distilled water (250 mL). The resultant was mixedhomogeneously and stood to separate. The organic phase was washed withsaturated NaCl aqueous solution (200 mL) once, dried over anhydrousMgSO₄ for 30 min, filtered and concentrated to give the target compound.

Preparation 19 2-(2-(2-(-aminoethoxy)ethoxy)ethoxy)ethanol hydrochloride

To a reaction flask was added concentrated hydrochloric acid (100.5 mL).The flask was cooled in an ice bath.2-(2-(2-(2-t-butoxyethoxy)ethoxy)ethoxy)ethylamine (123.7 g) wasdissolved in tetrahydrofuran (170 mL) (over about 2 hr). The resultantmixture was dropwise added to the reaction flask and reacted overnight.After the reaction was completed, the reaction solution was concentratedto remove tetrahydrofuran. The resultant crude product was dissolved inchloroform (150 mL) and distilled water (100 mL). The resultant solutionwas mixed homogeneously and stood to separate. The aqueous phase wasdirectly concentrated to give the target compound.

Preparation 20T-butyl-2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethylcaramate

To a reaction flask was added2-(2-(2-(-aminoethoxy)ethoxy)ethoxy)ethanol hydrochloride (41.6 g).Distilled water (80 mL) was added to dissolve2-(2-(2-(-aminoethoxy)ethoxy)ethoxy)ethanol hydrochloride. The solutionwas cooled in an ice bath. Anhydrous sodium carbonate (38.414 g) wasdissolved in distilled water (200 mL) (over 1 hr). The mixture wasdropwise added to the reaction flask. Di-t-butyl dicarbonate (51.370 g)was dissolved in tetrahydrofuran (120 mL). The mixture was dropwiseadded (over 160 min) to the reaction flask. The resultant mixturereacted overnight. After the reaction was completed, the reactionsolution was concentrated and then extracted with ethyl acetate (150 mL)once, extracted with dichloromethane (150 mL) once. Two organic phaseswere combined, dried over anhydrous MgSO₄ for 30 min, filtered andconcentrated to give the target compound.

Preparation 21t-butyl-2-(2-(2-(2-(p-methylphenoxy)ethoxy)ethoxy)ethoxy)ethylcaramate

To a reaction flask was addedt-butyl-2-(2-(2-(2-hydroxyethoxyl)ethoxy)ethoxy)ethylcarbamate (14.650g). Tetrahydrofuran (75 mL) was added to dissolvet-butyl-2-(2-(2-(2-hydroxyethoxyl)ethoxy)ethoxy)ethylcarbamate. To thereaction flask was added p-toluenesulfonyl chloride (11.439 g). Themixture was cooled in an ice bath. To the reaction flask was dropwiseadded 20% sodium hydroxide aqueous solution (18.684 g) (over 15 min).The ice bath was removed when the addition was completed. The resultantmixture was stirred at the room temperature until the reaction wascompleted (for about 5 hr). To the reaction flask was again added 20%sodium hydroxide aqueous solution (8.715 g). The mixture was stirred for2 hr in an oil bath at 40° C. The resultant solution was directly usedin the subsequent reaction.

Preparation 22t-butyl-2-(2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethoxy)ethylcaramate

To a reaction flask was added dimethylamine hydrochloride (40.766 g).Distilled water (60 mL) was added to dissolve dimethylaminehydrochloride. The solution was cooled in an ice bath. To the reactionflask was added 20% sodium hydroxide aqueous solution (101.464 g). Tothe reaction flask was added the solution obtained in Preparation 22.The mixture was stirred in an oil bath at 40° C. until the reaction wascompleted. After the reaction solution was concentrated to removetetrahydrofuran, dichloromethane (200 mL) was added. The mixture wasmixed homogeneously and stood to separate. The aqueous phase wasdiscarded. The organic phase was added into distilled water (100 mL).The pH of the mixture was adjusted with 2 N HCl to 3. The solution wasmixed homogeneously and stood to separate. The aqueous phase wasdirectly concentrated to give the target compound.

Preparation 232-(2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethoxy)ethlaminehydrochloride

To a reaction flask was addedt-butyl-2-(2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethoxy)ethylcarbamate(8.629 g). Tetrahydrofuran was added to dissolvet-butyl-2-(2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethoxy)ethylcarbamate.The resultant solution was cooled in an ice bath. To the reaction flaskwas added concentrated hydrochloric acid (20 mL) (over 20 min). Afterthe reaction was completed, the reaction solution was concentrated toremove tetrahydrofuran, and distilled water (50 mL) and dichloromethane(50 mL) were added. The resultant mixture was mixed homogeneously andstood to separate. The aqueous phase was directly concentrated to givethe target compound.

The target compounds in Preparation 24 to 104 were prepared according tothe preparation process in Preparation 4.

Preparation 24 4-(4-(methylsulfonyl)amino)-4-oxobutanoic AcidPreparation 25 4-(4-(phenyllsulfonyl)amino)-4-oxobutanoic AcidPreparation 26 4-(4-(morphholinylmethyl)phenylamino)-4-oxobutanoic AcidPreparation 27 4-(4-((dimethylamino)methyl)phenylamino)-4-oxobutanoicAcid Preparation 285-(4-((dimethylamino)methyl)phenylamino)-5-oxopentanoic Acid Preparation29 4-(2-(2-(dimethylamino)ethoxy)ethylamino)-4-oxobutanoic AcidPreparation 30 5-(2-(2-(dimethylamino)ethoxy)ethylamino)-5-oxopentanoicAcid Preparation 31 4-(4-(hydroxyethyl)piperazin-1-yl)-4-oxobutanoicAcid Preparation 32 5-(4-(hydroxyethyl)piperazin-1-yl)-5-oxopentanoicAcid Preparation 33 4-((morpholin-1-yl)amino)-4-oxobutanoic AcidPreparation 34 5-((morpholin-1-yl)amino)-5-oxopentanoic Acid Preparation35 4-(3-(morpholin-1-yl)propylamino)-4-oxobutanoic Acid Preparation 365-(3-(morpholin-1-yl)propylamino)-5-oxopentanoic Acid Preparation 374-((4-methylpiperazin-1-yl)amino)-4-oxobutanoic Acid Preparation 385-((4-methylpiperazin-1-yl)amino)-5-oxopentanoic Acid Preparation 394-(2-(tetrahydropyrrol-1-yl)ethylamino)-4-oxobutanoic Acid Preparation40 5-(2-(tetrahydropyrrol-1-yl)ethylamino)-5-oxopentanoic AcidPreparation 41 4-(3-(tetrahydropyrrol-1-yl)propylamino)-4-oxobutanoicAcid Preparation 425-(3-(tetrahydropyrrol-1-yl)propylamino)-5-oxopentanoic Acid Preparation43 4-((6-(morpholin-1-yl)pyridin-3-yl)amino)-4-oxobutanoic AcidPreparation 44 5-((6-(morpholin-1-yl)pyridin-3-yl)amino)-5-oxopentanoicAcid Preparation 45 4-((pyridin-4-yl)amino)-4-oxobutanoic AcidPreparation 46 5-((pyridin-4-yl)amino)-5-oxopentanoic Acid Preparation47 4-((pyridin-3-yl)amino)-4-oxobutanoic Acid Preparation 484-((pyridin-3-yl)amino)-4-oxopentanoic Acid Preparation 494-((pyridin-4-yl)methylamino)-4-oxobutanoic Acid Preparation 505-((pyridin-4-yl)methylamino)-5-oxopentanoic Acid Preparation 514-((pyridin-3-yl)methylamino)-4-oxobutanoic Acid Preparation 525-((pyridin-3-yl)methylamino)-5-oxopentanoic Acid Preparation 534-((pyridin-2-yl)methylamino)-4-oxobutanoic Acid Preparation 545-((pyridin-2-yl)methylamino)-5-oxopentanoic Acid Preparation 554-(2-(pyridin-4-yl)ethylamino)-4-oxobutanoic Acid Preparation 565-(2-(pyridin-4-yl)ethylamino)-5-oxopentanoic Acid Preparation 574-(2-(pyridin-2-yl)ethylamino)-4-oxobutanoic Acid Preparation 585-(2-(pyridin-2-yl)ethylamino)-5-oxopentanoic Acid Preparation 594-(2-(pyridin-3-yl)ethylamino)-4-oxobutanoic Acid Preparation 605-(2-(pyridin-3-yl)ethylamino)-5-oxopentanoic Acid Preparation 614-(2-(4-(aminosulfonyl)phenyl)ethylamino)-4-oxobutanoic Acid Preparation62 5-(2-(4-(aminosulfonyl)phenyl)ethylamino)-5-oxopentanoic AcidPreparation 63 4-(4-ethylpiperazin-1-yl)-4-oxobutanoic Acid Preparation64 5-(4-ethylpiperazin-1-yl)-5-oxopentanoic Acid Preparation 654-(purineamino)-4-oxobutanoic acid Preparation 665-(purineamino)-5-oxopentanoic acid Preparation 674-(4-(3-(dimethylamino)propyl)piperazin-1-yl)-4-oxobutanoic AcidPreparation 685-(4-(3-(dimethylamino)propyl)piperazin-1-yl)-5-oxopentanoic AcidPreparation 69 4-(3-(4-methylpiperazin-1-yl)propylamino)-4-oxobutanoicAcid Preparation 705-(3-(4-methylpiperazin-1-yl)propylamino)-5-oxopentanoic AcidPreparation 71 4-(2-(dimethylamino)ethylamino)-4-oxobutanoic AcidPreparation 72 5-(2-(dimethylamino)ethylamino)-5-oxopentanoic AcidPreparation 73 4-(DI(2-(dimethylamino)ethyl)amino)-4-oxobutanoic AcidPreparation 74 5-(DI(2-(dimethylamino)ethyl)amino)-5-oxopentanoic AcidPreparation 754-(2-(2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethoxy)ethylamino)-4-oxobutanoicAcid Preparation 765-(2-(2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethoxy)ethylamino)-5-oxopentanoicAcid Preparation 77 4-((pyrazin-2-yl)amino)-4-oxobutanoic AcidPreparation 78 5-((pyrazin-2-yl)amino)-5-oxopentanoic Acid Preparation79 4-((pyridin-2-yl)amino)-4-oxobutanoic Acid Preparation 805-((pyridin-2-yl)amino)-5-oxopentanoic Acid Preparation 814-((pyrimidin2-yl)amino)-4-oxobutanoic Acid Preparation 825-((pyrimidin2-yl)amino)-5-oxopentanoic Acid Preparation 834-(2-hydroxyethylamino)-4-oxobutanoic Acid Preparation 845-(2-hydroxyethylamino)-5-oxopentanoic Acid Preparation 854-(2-(2-hydroxyethoxy)ethylamino)-4-oxobutanoic Acid Preparation 865-(2-(2-hydroxyethoxy)ethylamino)-5-oxopentanoic Acid Preparation 874-(DI(2-(hydroxy)ethyl)amino)-4-oxobutanoic Acid Preparation 885-(DI(2-(hydroxy)ethyl)amino)-5-oxopentanoic Acid Preparation 894-amino-4-oxobutanoic Acid Preparation 90 5-amino-5-oxopentanoic AcidPreparation 91 4-methylamino-4-oxobutanoic Acid Preparation 925-methylamino-5-oxopentanoic Acid Preparation 934-Dimethylamino-4-oxobutanoic Acid Preparation 945-Dimethylamino-5-oxopentanoic Acid Preparation 954-(morpholin-1-yl)-4-oxobutanoic Acid Preparation 965-(morpholin-1-yl)-5-oxopentanoic Acid Preparation 974-(piperidin-1-yl)-4-oxobutanoic Acid Preparation 984-(tetrahydropyrrol-1-yl)-4-oxobutanoic Acid Preparation 994-(2-(morpholin-1-yl)ethylamino)-4-oxobutanoic Acid Preparation 1004-(2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethylamino)-4-oxobutanoicAcid Preparation 1014-(2-(2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ETHOXY)ethylamino)-4-oxobutanoicAcid Preparation 1024-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxy)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ethylamino)-4-oxobutanoicAcid Preparation 1034-(2-(2-(2-(2-(2-(2-(2-(2-(2-(METHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ethylamino)-4-oxobutanoicAcid Preparation 1044-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethylamino)-4-oxobutanoic acidExample 110-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethylamino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedione

To a reaction flask was added the compound (99 mg) obtained inPreparation 1. Dichloromethane (5 mL, dried via molecular sieves) wasadded to dissolve the compound. To the resultant solution were added thecompound (82 mg) obtained in Preparation 104 and DMAP (8 mg). Themixture was stirred under the protection of argon gas. EDC.HCl (50 mg)was added. The mixture reacted overnight at the room temperature. Afterthe reaction was completed, the reaction solution was concentrated andthen directly purified by thin layer chromatography (the developingsolvent was chloroform (CHCl₃):methanol (CH₃OH)=95:5, 5 mL, adding onedrop of glacial acetic acid), to give the target compound. MS: 867.1(M-1)

The compounds listed in Table 1 were prepared according to thepreparation process in Example 1, in which the dashed line in thesubstituents represented the linking bond.

TABLE 1 Examples n NR²R³ Mass Spectra (MS)  2 2

MS: 868.1 (M + 1)  3 3

MS: 882.3 (M + 1)  4 2

MS⁺ 825.9  5 3

MS: 840.3 (M + 1)  6 2

MS⁻ 806.2 (M − 1) MS⁺ 808.3 (M + 1))  7 3

MS⁺ 822.3 (M + 1)  8 2

MS⁺ 806.1 (M + 1)  9 3

MS⁺ 820.1 (M + 1) 10 2

MS⁻: 775.8 (M − 1) 11 3

MS⁺: 791.2 (M + 1) 12 2

MS⁺: 820.4 (M + 1) MS⁻: 818.6 (M − 1) 13 3

MS⁺: 834.8 (M + 1) 14 2

MS⁻: 788.9 (M − 1) 15 3

MS⁺: 805.8 (M + 1) 16 2

MS⁺ 790.3 (M + 1) 17 3

MS⁺ 804.4 (M + 1) 18 2

MS⁺: 804.1 (M + 1) 19 3

MS⁺: 817.2 (M + 1) 20 2

MS⁻: 853.3 (M − 1) MS⁺: 855.4 (M + 1) 21 3

MS⁺: 869.3 (M + 1) 22 2

MS⁺: 770.0 (M + 1) MS⁻: 767.7 (M − 1) 23 3

MS⁺: 784.7 (M + 1) 24 2

MS⁺: 770.1 (M + 1) 25 3

MS⁺: 784.6 (M + 1) 26 2

MS⁺: 784.0 (M + 1) 27 3

MS⁺: 798.2 (M + 1) 28 2

MS⁺: 783.9 (M + 1) MS⁻: 781.8 (M − 1) 29 3

MS⁺: 798.9 (M + 1) 30 2

MS⁺: 784.1 (M + 1) 31 3

MS⁺: 798.1 (M + 1) 32 2

MS⁺: 798.0 (M + 1) 33 3

MS⁺: 812.1 (M + 1) 34 2

MS⁺: 798.0 (M + 1) 35 3

MS⁺: 812.3 (M + 1) 36 2

MS⁺: 798.0 (M + 1) 37 3

MS⁺: 812.1 (M + 1) 38 2

MS⁻: 873.7 (M − 1) 39 3

MS⁻: 888.1 (M − 1) 40 2

MS⁺: 790.1 (M + 1) 41 3

MS⁺: 804.3 (M + 1) 42 2

MS⁺: 811.0 (M + 1) MS⁻: 809.2 (M − 1) 43 3

MS⁺: 825.4 (M + 1) 44 2

MS⁺: 847.1 (M + 1) MS⁻: 845.0 (M − 1) 45 3

MS⁺: 860.3 (M + 1) 46 2

MS⁺: 833.1 (M + 1) 47 3

MS⁺: 847.2 (M + 1) 48 2

MS⁺: 764.1 (M + 1) 49 3

MS⁺: 778.1 (M + 1) 50 2

MS⁺: 835.2 (M + 1) 51 3

MS⁺: 849.2 (M + 1) 52 2

MS⁺ 896.1 (M + 1) 53 3

MS⁺ 909.8 (M + 1) 54 2

MS⁺ 771.2 (M + 1) 55 3

MS⁺ 784.1 (M + 1) 56 2

MS⁺ 770.1 (M + 1) 57 3

MS⁺ 784.1 (M + 1) 58 2

MS⁺ 770.1 (M + 1) 59 3

MS⁺ 784.1 (M + 1) 60 2

MS⁻: 735.2 (M − 1) MS⁺: 759.3 (M + Na⁺) 61 3

MS⁻: 750.7 (M − 1) 62 2

MS⁺: 803.3 (M + Na⁺) 63 3

MS⁻: 793.6 (M − 1) 64 2

MS⁺: 803.2 (M + Na⁺) MS⁻: 779.2 (M − 1) 65 3

MS⁺: 795.2 (M + 1) 66 2 NH₂ MS⁺: 693.1 (M + 1) 67 3 NH₂ MS⁺: 707.2(M + 1) 68 2 NHCH₃ MS⁻: 705.6 (M − 1) 69 3 NHCH₃ MS⁺: 721.1 (M + 1) 70 2N(CH₃)₂ MS⁺: 721.1 (M + 1) 71 3 N(CH₃)₂ MS⁺: 735.6 (M + 1) 72 2

MS⁺: 763.2 (M + 1) 73 3

MS⁺: 777.1 (M + 1) 74 2

MS⁺: 761.3 (M + 1) 75 2

MS⁺: 746.9 (M + 1) 88 2

MS⁺: 806.2 (M + 1) 90 2

91 2

92 2

93 2

94 2

MS⁺: 771 (M + 1) 95 2

MS⁺: 833 (M + 1) 97 3

98 2

The ¹H-NMR spectra data of the compound in Example 28 were:

δ=1.145 ppm (d, 3H), δ=1.664 ppm (m, 1H), δ=2.110 ppm (m, 1H),

δ=2.336 ppm (d, 1H), δ=2.415 ppm (m, 1H), δ=2.505 ppm (m, 2H),

δ=2.675 ppm (t, 2H), δ=2.917 ppm (d, 1H), δ=3.008 ppm (d, 1H),

δ=3.546 ppm (s, 1H), δ=3.943 ppm (s, 4H), δ=4.303 ppm (m, 5H),

δ=4.982 ppm (s, 1H), δ=5.189 ppm (d, 1H), δ=5.253 ppm (d, 1H),

δ=5.349 ppm (s, 1H), δ=5.920 ppm (s, 2H), δ=6.780 ppm (s, 2H),

δ=7.346 ppm (m, 1H), δ=7.609 ppm (d, 1H), δ=7.640 ppm (d, 1H),

δ=7.856 ppm (m, 2H), δ=8.471 ppm (m, 3H), δ=13.219 ppm (s, 1H),

δ=13.982 ppm (s, 1H)

The ¹H-NMR spectra data of the compound in Example 88 were:

δ=1.149 ppm (d, 3H), δ=2.646 ppm (d, 2H), δ=2.409 ppm (t, 2H),

δ=1.375-2.445 ppm (m, 2H), δ=2.795-2.936 ppm (dd, 2H),

δ=2.702 ppm (s, 4H), δ=4.294 ppm (m, 1H), δ=3.869 ppm (s, 3H),

δ=2.632 ppm (d, 2H), δ=3.666 ppm (t, 4H),

δ=5.162-5.236 ppm (dd, 2H), δ=4.282 ppm (m, 1H),

δ=4.897 ppm (s, 1H), δ=3.533 ppm (s, 1H), δ=5.314 ppm (s, 1H),

δ=5.899 ppm (t, 2H), δ=7.729 ppm (d, 1H), δ=6.755 ppm (t, 2H),

δ=7.492 ppm (d, 1H), δ=7.772 ppm (t, 1H), δ=8.070 ppm (t, 1H),

δ=13.097 ppm (bs, 1H), δ=13.871 ppm (s, 1H)

Example 7610-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(2-(dimethylamino)ethoxy)ethylamino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate

The target compound (10 mg) obtained in Example 6 was dissolved inchloroform (10 mL) with stirring. To a reaction flask was added glacialacetic acid (1 mg) dissolved in chloroform (10 mL). The mixture wascontinuously stirred for 10 min, and rotary-evaporated to remove thesolvent, thereby giving the target compound.

The solubility of the compound in water was more than 9 mg/mL.

The target compounds in Examples 77-87 and 89 were prepared according tothe preparation process in Example 76.

Example 7710-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((4-(2-hydroxy)ethyl)piperazin-1-yl)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate

The solubility of the compound in water was more than 10.6 mg/ml.

Example 7810-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((3-(morpholin-1-yl)propyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate

The solubility of the compound in water was more than 22 mg/ml.

Example 7910-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((4-methyl)piperazin-1-yl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedinoeacetate

The solubility of the compound in water was more than 5 mg/ml.

Example 8010-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(4-ethylpiperazin-1-yl)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate

The solubility of the compound in water was more than 11 mg/ml.

Example 8110-((3′-(pyrrol-1-yll)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate

The solubility of the compound in water was more than 7 mg/ml.

Example 8210-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((pyridin-4-yl)methyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate

The solubility of the compound in water was more than 6 mg/ml.

Example 8310-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((pyridin-3-yl)methyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate

The solubility of the compound in water was more than 1 mg/ml.

Example 8410-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(pyridin-2-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate

The solubility of the compound in water was more than 12 mg/ml.

Example 8510-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(pyridin-3-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate

The solubility of the compound in water was more than 11 mg/ml.

Example 8610-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(pyridin-4-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate

The solubility of the compound in water was more than 3 mg/ml.

Example 8710-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(4-(3-(dimethylamino)propyl)piperazin-1-yl)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate

The solubility of the compound in water was more than 16 mg/ml.

Example 8910-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((2-(morpholin-1-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate Example 9610-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((2-(morpholin-1-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedionephosphate

The solubility of the compound in water was more than 26 mg/ml.

The compound in Example 96 was detected by HPLC after being sealed andstored for 9 months under refrigeration conditions. No obvious degradedproduct was observed, which indicates good stability of the compound.

Example 9910-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-l-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((2-(morpholin-1-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedionehydrochloride BIOLOGICAL ACTIVITY EXAMPLES Example 1 SK-OV-3 Cell GrowthInhibition Test (MTT Assay)

I. Assay Materials

Cell strains: SK-OV-3 (human ovarian cancer cell strains); MTT;antitumor compounds; DMSO.

II. Reagents and Consumable Materials

Culture medium: 90% McCoy's 5A+10% FBS; Pancreatin (0.25% (w/v) solutionwas formulated with PBS, 0.53 mM of EDTA was added in the formulation);PBS; 96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. PBS was sucked out. 1.5 mL of 0.25% pancreatin was added toinfiltrate the cells;

4. The pancreatin was sucked out. The culture plate was placed in anincubator. Digestion was carried out for about 5 min at 37° C.;

5. 4.5 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 ml) to give a uniform cell suspension. The suspension was implantedinto a 96-well cell culture disc by 4000 cells/100 μL per well. Theculture plate was incubated overnight under 5% CO₂ at 37° C. In day 2,100 μL of culture solution comprising a compound was added in each well.The plate was further incubated for 69 h under 5% CO₂ at 37° C.;

6. The culture solution was sucked out;

7. 100 μL of serum-free culture solution containing 0.5 mg/mL MTT wasadded in each well. The plate was incubated for 3 h;

8. The culture solution was carefully sucked out;

9. 100 μL of DMSO was added in each well and vibrated to dissolve;

10. OD values were determined at 490 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 2 Growth Inhibition Activity at 667 nM of Some Compounds inExamples on SK-OV-3 Cells Inhi- Inhi- Inhi- bition bition bition RatioRatio Ratio Compounds (%) Compounds (%) Compounds (%) Example 1 57.3Example 3 62.5 Example 8 60   Example 10 71.5 Example 12 48.8 Example 1453.6 Example 18 47.4 Example 20 62.6 Example 22 60.3 Example 24 61.4Example 26 67.6 Example 28 66.2 Example 30 59.9 Example 32 59.7 Example34 59.4 Example 35 57.8 Example 38 67.6 Example 40 47.9 Example 44 52.3Example 60 58.9 Example 62 63.6 Example 64 65.9 Example 66 66.5 Example76 46.4 Example 77 60.4 Example 81 56.4 Example 94 71.4 Example 95 66.3

Example 2 BxPc-3 Cell Growth Inhibition Test (MTT Assay)

I. Assay Materials:

Cell strains: BxPC-3 (human pancreatic cancer cell strains); MTT;antitumor compounds; DMSO.

II. Reagents and Consumable Materials

Culture medium: 90% RPMI-1640+10% FBS; Pancreatin (0.25% (w/v) solutionwas formulated with PBS, 0.53 mM of EDTA was added in the formulation);PBS; 96-well culture plate.

III. Assay Process:

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. PBS was sucked out. 1.5 mL of 0.25% pancreatin was added toinfiltrate the cells;

4. The culture plate was placed in an incubator. Digestion was carriedout for about 8 min at 37° C.;

5. 4.5 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 ml) to give a uniform cell suspension. The suspension was implantedinto a 96-well cell culture disc by 5000 cells/100 μL per well. Theculture plate was incubated overnight under 5% CO₂ at 37° C. In day 2,100 μL of culture solution comprising a compound was added in each well.The plate was further incubated for 70 h under 5% CO₂ at 37° C.;

6. The culture solution was sucked out;

7. 100 μL of serum-free culture solution containing 0.5 mg/mL MTT wasadded in each well. The plate was incubated for 3 h;

8. The culture solution was carefully sucked out;

9. 100 μL of DMSO was added into each well and vibrated to dissolve;

10. OD values were determined at 490 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 3 Growth Inhibition Activity at 2000 nM of Some Compounds inExamples on BxPc-3 Cells Inhi- Inhi- Inhi- bition bition bition RatioRatio Ratio Compounds (%) Compounds (%) Compounds (%) Example 1 82.5Example 3 81.2 Example 8 82.6 Example 10 85   Example 12 74.9 Example 1481.8 Example 18 70.7 Example 20 84.1 Example 22 82   Example 24 84.7Example 26 82.7 Example 28 84.7 Example 30 85.2 Example 32 83.4 Example34 84   Example 35 81.3 Example 38 82.4 Example 40 76.5 Example 44 78.5Example 60 83.4 Example 62 82.5 Example 64 83.7 Example 66 83.1 Example76 77.1 Example 77 83.3 Example 81 80.7 Example 94 84.9 Example 95 80.6

Example 3 NCI-H446 Cell Growth Inhibition Test (MTT Assay)

I. Assay Materials

Cell strains: NCI-H446 (human small cell lung cancer cell strains); MTT;antitumor compounds; DMSO.

II. Reagents and Consumable Materials

Culture medium: 90% RPMI-1640+10% FBS; Pancreatin (0.25% (w/v) solutionwas formulated with PBS, 0.53 mM of EDTA was added in the formulation);PBS; 96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. PBS was sucked out. 1.5 mL of 0.25% pancreatin was added toinfiltrate the cells;

4. The culture plate was placed in an incubator. Digestion was carriedout for about 3 min at 37° C.;

5. 3 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 ml) to give a uniform cell suspension. The suspension was implantedinto a 96-well cell culture disc by 4000 cells/100 μL per well. Theculture plate was incubated overnight under 5% CO₂ at 37° C. In day 2,100 μL of culture solution comprising a compound was added in each well.The plate was further incubated for 70 h under 5% CO₂ at 37° C.;

6. The culture solution was sucked out;

7. 100 μL of serum-free culture solution containing 0.5 mg/mL MTT wasadded in each well. The plate was incubated for 3 h;

8. The culture solution was carefully sucked out;

9. 100 μL of DMSO was added into each well and vibrated to dissolve;

10. OD values were determined at 490 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 4 Growth Inhibition Activity at 222 nM of Some Compounds inExamples on NCI-H446 Cells Inhi- Inhi- Inhi- bition bition bition RatioRatio Ratio Compounds (%) Compounds (%) Compounds (%) Example 1 43.2Example 3 60.8 Example 8 59.5 Example 10 61.1 Example 12 54.6 Example 2068   Example 22 62.1 Example 24 61.8 Example 26 66.9 Example 28 65.8Example 30 61   Example 32 59.3 Example 34 60.7 Example 35 57.2 Example38 62.6 Example 40 49   Example 44 46.3 Example 60 52.5 Example 62 64.6Example 64 51.6 Example 66 56.2 Example 76 46   Example 77 59.1 Example81 56.8 Example 94 48.4

Example 4 MDA-MB-453 Cell Growth Inhibition Test (SRB Assay)

I. Assay Materials

Cell strains: MDA-MB-453 (human breast cancer cell strains); SRB: 0.4%(w/v) working solution was formulated with 1% glacial acetic acid,reserved at 4° C.; antitumor compounds; DMSO.

II. Reagents and Consumable Materials

Culture medium: 90% L15+10% FBS; pancreatin (0.25% (w/v) solution wasformulated with PBS, 0.53 mM of EDTA was added in the formulation); PBS;96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. 1.5 mL of 0.25% pancreatin was added to the plate to infiltrate thecells;

4. The pancreatin was sucked out. The culture plate was placed in anincubator. Digestion was carried out for about 3 min at 37° C.;

5. 4 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 ml) to give a uniform single cell suspension. The suspension wasimplanted into a 96-well cell culture plate by 7000 cells/100 μL perwell. The culture plate was incubated overnight under 5% CO₂ at 37° C.In day 2, 100 μL of culture solution comprising a compound was added ineach well.

The plate was further incubated for 69.5 h under 5% CO₂ at 37° C.;

6. The culture solution was sucked out. 100 uL of TCA fixed cells whichwere diluted to 10% were added to each well. The plate was kept in arefrigerator for 1 h at 4° C.

7. TCA stationary liquid was sucked out. Each well was washed with 150μL of ddH₂O five times;

8. After the stationary liquid was cleansed, the plate was dried in theair at the room temperature;

9. 60 μL of SRB staining solution was added in each well. The well wasstained for 15 min at the room temperature;

10. The SRB staining solution was sucked out. Each well was washed with150 μL of 1% glacial acetic acid five times;

11. After the SRB staining solution was cleansed, the plate was dried inthe air at the room temperature;

12. 100 μL of 10 mM Tris was added in each well. The plate was vibratedto dissolve out SRB;

13. OD values were determined at 570 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 5 Growth Inhibition Activity at 2000 nM of Some Compounds inExamples on MDA-MB-453 Cells Inhibition Compounds Ratio (%) Example 177.7 Example 3 73.9 Example 8 75.3 Example 10 78.5 Example 12 73.7Example 14 74.4 Example 20 82.4 Example 22 71.1 Example 24 79.8 Example26 79.9 Example 28 81.9 Example 30 79.9 Example 32 78.3 Example 34 80.5Example 35 77.1 Example 38 75.8 Example 40 73 Example 44 68.5 Example 6076.3 Example 62 83.7 Example 64 73.5 Example 66 73.9 Example 76 62.7Example 77 79.7 Example 81 72 Example 94 75.8 Example 95 68.2

Example 5 22Rv1 Cell Growth Inhibition Test (SRB Assay)

I. Assay Materials

Cell strains: 22Rv1 (human prostate cancer cell strains); SRB: 0.4%(w/v) working solution was formulated with 1% glacial acetic acid,reserved at 4° C.; antitumor compounds; DMSO.

II. Reagents and Consumable Materials

Culture medium: 90% RPMI-1640+10% FBS; Pancreatin (0.25% (w/v) solutionwas formulated with PBS, 0.53 mM of EDTA was added in the formulation);PBS; 96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. 1.5 mL of 0.25% pancreatin was added to the plate to infiltrate thecells;

4. The pancreatin was sucked out. The culture plate was placed in anincubator. Digestion was carried out for about 3 min at 37° C.;

5. 4 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 ml) to give a uniform single cell suspension. The suspension wasimplanted into a 96-well cell culture plate by 7000 cells/100 μL perwell. The culture plate was incubated overnight under 5% CO₂ at 37° C.In day 2, 100 μL of culture solution comprising a compound was added ineach well. The plate was further incubated for 73 h under 5% CO₂ at 37°C.;

6. The culture solution was sucked out. 100 uL of TCA fixed cells whichwere diluted to 10% were added to each well. The plate was kept in arefrigerator for 1 h at 4° C.

7. TCA stationary liquid was sucked out. Each well was washed with 150μL of ddH₂O five times;

8. After the stationary liquid was cleansed, the plate was dried in theair at the room temperature;

9. 60 μL of SRB staining solution was added in each well. The well wasstained for 15 min at the room temperature;

10. The SRB staining solution was sucked out. Each well was washed with150 μL of 1% glacial acetic acid five times;

11. After the SRB staining solution was cleansed, the plate was dried inthe air at the room temperature;

12. 100 μL of 10 mM Tris was added in each well. The plate was vibratedto dissolve out SRB;

13. OD values were determined at 570 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 6 Growth Inhibition Activity at 222 nM of Some Compounds inExamples on 22Rv1 Cells Inhibition Compounds Ratio (%) Example 1 52.2Example 3 61.9 Example 8 56.8 Example 10 62.7 Example 12 53.3 Example 1452.1 Example 20 60.9 Example 22 56.3 Example 24 63.6 Example 26 60.8Example 28 63.1 Example 30 62.3 Example 32 61.7 Example 34 63.3 Example35 58.5 Example 38 56.3 Example 40 50.5 Example 44 48.5 Example 60 52.9Example 62 57 Example 64 54.8 Example 66 59 Example 76 49.2 Example 7757.9 Example 81 56.5 Example 94 60.7 Example 95 51.3

Example 6 A375 Cell Growth Inhibition Test (MTT Assay)

I. Assay Materials

Cell strains: A375 (human cutaneous melanoma cell strains); MTT:nitroblue tetrazolium; antitumor compounds; compound A:3′-pyrrolyldoxorubicin-14-oxo-succinic acid monoester; DMSO.

II. Reagents and Consumable Materials

Culture medium: 90% DMEM+10% FBS (fetal calf serum); Pancreatin (0.25%(w/v) solution was formulated with PBS, 0.53 mM of EDTA was added in theformulation); PBS; 96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. PBS was sucked out. 1.5 mL of 0.25% pancreatin was added to the plateto infiltrate the cells for 1 min;

4. The culture plate was placed in an incubator. Digestion was carriedout for about 5 min at 37° C.;

5. 3 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 ml) to give a uniform cell suspension. The suspension was implantedinto a 96-well cell culture disc by 3000 cells/100 μL per well. Theculture plate was incubated overnight under 5% CO₂ at 37° C. In day 2,100 μL of culture solution comprising a compound was added in each well.The plate was further incubated for 72 h under 5% CO₂ at 37° C.;

6. The culture solution was sucked out;

7. 100 μL of serum-free culture solution containing 0.5 mg/mL MTT wasadded in each well. The plate was incubated for 3 h;

8. The culture solution was carefully sucked out;

9. 100 μL of DMSO was added in each well and vibrated to dissolve;

10. OD values were determined at 490 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 7 Growth Inhibition Activity of Some Compounds in Examples on A375Cells Inhibition Inhibition Inhibition Com- Activity Com- Activity Com-Activity pounds (IC₅₀/nM) pounds (IC₅₀/nM) pounds (IC₅₀/nM) Com- 207Exam- 67 Exam- 48 pound A ple 6 ple 89 Exam- 67 Exam- 28 Exam- 35 ple 81ple 97 ple 99

Example 7 A431 Cell Growth Inhibition Test (MTT Assay)

I. Assay Materials

Cell strains: A431 (human epidermal carcinoma cell strains); MTT:nitroblue tetrazolium; antitumor compounds; compound A:3′-pyrrolyldoxorubicin-14-oxo-succinic acid monoester; DMSO.

II. Reagents and Consumable Materials

Culture medium: 45% DMEM+45% F12+10% FBS (fetal calf serum); Pancreatin(0.25% (w/v) solution was formulated with PBS, 0.53 mM of EDTA was addedin the formulation); PBS; 96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. PBS was sucked out. 1.5 mL of 0.25% pancreatin was added to the plateto infiltrate the cells for 1 min;

4. The culture plate was placed in an incubator. Digestion was carriedout for about 5 min at 37° C.;

5. 3 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 mL) to give a uniform cell suspension. The suspension was implantedinto a 96-well cell culture disc by 2500 cells/100 μL per well. Theculture plate was incubated overnight under 5% CO₂ at 37° C. In day 2,100 μL of culture solution comprising a compound was added in each well.The plate was further incubated for 72 h under 5% CO₂ at 37° C.;

6. The culture solution was sucked out;

7. 100 μL of serum-free culture solution containing 0.5 mg/mL MTT wasadded in each well. The plate was incubated for 3 h;

8. The culture solution was carefully sucked out;

9. 100 μL of DMSO was added in each well and vibrated to dissolve;

10. OD values were determined at 490 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 8 Growth Inhibition Activity of Some Compounds in Examples on A431Cells Inhibition Activity Compounds (IC₅₀/nM) Compound A 68 Example 8142 Example 89 46 Example 97 45

Example 8 MCF-7 Cell Growth Inhibition Test (SRB Assay)

I. Assay Materials

Cell strains: MCF-7 (human breast cancer cell strains); SRB: 0.4% (w/v)working solution was formulated with 1% glacial acetic acid, reserved at4° C.; antitumor compounds; compound A:3′-pyrrolyldoxorubicin-14-oxo-succinic acid monoester; DMSO.

II. Reagents and Consumable Materials

Culture medium: 90% EMEM+10% FBS; Pancreatin (0.25% (w/v) solution wasformulated with PBS, 0.53 mM of EDTA was added in the formulation); PBS;96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. 1.5 mL of 0.25% pancreatin was added to the plate to infiltrate thecells;

4. The pancreatin was sucked out. The culture plate was placed in anincubator. Digestion was carried out for about 3 min at 37° C.;

5. 4 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 mL) to give a uniform single cell suspension. The suspension wasimplanted into a 96-well cell culture plate by 10000 cells/100 μL perwell. The culture plate was incubated overnight under 5% CO₂ at 37° C.In day 2, 100 μL of culture solution comprising a compound was added ineach well. The plate was further incubated for 73 h under 5% CO₂ at 37°C.;

6. The culture solution was sucked out. 100 uL of TCA fixed cells whichwere diluted to 10% were added to each well. The plate was kept in arefrigerator for 1 h at 4° C.

7. TCA stationary liquid was sucked out. Each well was washed with 150μL of ddH₂O five times;

8. After the stationary liquid was cleansed, the plate was dried in theair at the room temperature;

9. 60 μL of SRB staining solution was added in each well. The well wasstained for 15 min at the room temperature;

10. The SRB staining solution was sucked out. Each well was washed with150 μL of 1% glacial acetic acid five times;

11. After the SRB staining solution was cleansed, the plate was dried inthe air at the room temperature;

12. 100 μL of 10 mM Tris was added in each well. The plate was vibratedto dissolve out SRB;

13. OD values were determined at 570 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 9 Growth Inhibition Activity of Some Compounds in Examples onMCF-7 Cells Inhibition Activity Compound (IC₅₀/nM) Compound A 785Example 81 225 Example 89 333

Example 9 NCI-446 Cell Growth Inhibition Test (MTT Assay)

I. Assay Materials

Cell strains: NCI-446 (human small cell lung cancer cell strains); MTT:nitroblue tetrazolium; antitumor compounds; compound A:3′-pyrrolyldoxorubicin-14-oxo-succinic acid monoester; DMSO.

II. Reagents and Consumable Materials Culture medium: 90% RPMI1640+10%FBS (fetal calf serum); Pancreatin (0.25% (w/v) solution was formulatedwith PBS, 0.53 mM of EDTA was added in the formulation); PBS; 96-wellculture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mlof PBS once or twice;

3. PBS was sucked out. 1.5 mL of 0.25% pancreatin was added to the plateto infiltrate the cells for 1 min;

4. The culture plate was placed in an incubator. Digestion was carriedout for about 3 min at 37° C.;

5. 3 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 mL) to give a uniform cell suspension. The suspension was implantedinto a 96-well cell culture disc by 4000 cells/100 μL per well. Theculture plate was incubated overnight under 5% CO₂ at 37° C. In day 2,100 μL of culture solution comprising a compound was added in each well.The plate was further incubated for 72 h under 5% CO₂ at 37° C.;

6. The culture solution was sucked out;

7. 100 μL of serum-free culture solution containing 0.5 mg/mL MTT wasadded in each well. The plate was incubated for 3 h;

8. The culture solution was carefully sucked out;

9. 100 μL of DMSO was added in each well and vibrated to dissolve;

10. OD values were determined at 490 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 10 Growth Inhibition Activity of Some Compounds in Examples onNCI-446Cells Inhibition Activity Compound (IC₅₀/nM) Compound A 234Example 89 140

Example 10 NCI-H460 Cell Growth Inhibition Test (MTT Assay)

I. Assay Materials

Cell strains: NCI-H460 (human large cell lung cancer cell strains); MTT:nitroblue tetrazolium; antitumor compounds; compound A:3′-pyrrolyldoxorubicin-14-oxo-succinic acid monoester; DMSO.

II. Reagents and Consumable Materials

Culture medium: 90% RPMI1640+10% FBS (fetal calf serum); Pancreatin(0.25% (w/v) solution was formulated with PBS, 0.53 mM of EDTA was addedin the formulation); PBS; 96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. PBS was sucked out. 1.5 mL of 0.25% pancreatin was added to the plateto infiltrate the cells for 1 min;

4. The culture plate was placed in an incubator. Digestion was carriedout for about 3 min at 37° C.;

5. 3 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 mL) to give a uniform cell suspension. The suspension was implantedinto a 96-well cell culture disc by 2000 cells/100 μL per well. Theculture plate was incubated overnight under 5% CO₂ at 37° C. In day 2,100 μL of culture solution comprising a compound was added in each well.The plate was further incubated for 72 h under 5% CO₂ at 37° C.;

6. The culture solution was sucked out;

7. 100 μL of serum-free culture solution containing 0.5 mg/mL MTT wasadded in each well. The plate was incubated for 3 h;

8. The culture solution was carefully sucked out;

9. 100 μL of DMSO was added in each well and vibrated to dissolve;

10. OD values were determined at 490 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 11 Growth Inhibition Activity of Some Compounds in Examples onNCI-460 Cells Inhibition Activity Compound (IC₅₀/nM) Compound A 21Example 89 2.5

Example 11 B16 Cell Growth Inhibition Test (MTT Assay)

I. Assay Materials

Cell strains: B16 (mouse melanoma cell strains); MTT: nitrobluetetrazolium; antitumor compounds; compound A:3′-pyrrolyldoxorubicin-14-oxo-succinic acid monoester; DMSO.

II. Reagents and Consumable Materials

Culture medium: 90% RPMI1640+10% FBS (fetal calf serum); Pancreatin(0.25% (w/v) solution was formulated with PBS, 0.53 mM of EDTA was addedin the formulation); PBS; 96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. PBS was sucked out. 1.5 mL of 0.25% pancreatin was added to the plateto infiltrate the cells for 1 min;

4. The culture plate was placed in an incubator. Digestion was carriedout for about 1 min at 37° C.;

5. 3 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 mL) to give a uniform cell suspension. The suspension was implantedinto a 96-well cell culture disc by 2500 cells/100 μL per well. Theculture plate was incubated overnight under 5% CO₂ at 37° C. In day 2,100 μL of culture solution comprising a compound was added in each well.The plate was further incubated for 72 h under 5% CO₂ at 37° C.;

6. The culture solution was sucked out;

7. 100 μl of serum-free culture solution containing 0.5 mg/mL MTT wasadded in each well. The plate was incubated for 3 h;

8. The culture solution was carefully sucked out;

9. 100 μL of DMSO was added in each well and vibrated to dissolve;

10. OD values were determined at 490 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 12 Growth Inhibition Activity of Some Compounds in Examples on B16Cells Inhibition Activity Compound (IC₅₀/nM) Compound A 32 Example 62 3Example 89 3

Example 12 786-O Cell Growth Inhibition Test (MTT Assay)

I. Assay Materials

Cell strains: 786-O (human clear cell adenocarcinoma cell strains); MTT:nitroblue tetrazolium; antitumor compounds; compound A:3′-pyrrolyldoxorubicin-14-oxo-succinic acid monoester; DMS 0.

II. Reagents and Consumable Materials

Culture medium: 90% RPMI1640+10% FBS (fetal calf serum); Pancreatin(0.25% (w/v) solution was formulated with PBS, 0.53 mM of EDTA was addedin the formulation); PBS; 96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. PBS was sucked out. 1.5 mL of 0.25% pancreatin was added to the plateto infiltrate the cells for 1 min;

4. The culture plate was placed in an incubator. Digestion was carriedout for about 1 min at 37° C.;

5. 3 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 mL) to give a uniform cell suspension. The suspension was implantedinto a 96-well cell culture disc by 2000 cells/100 μL per well. Theculture plate was incubated overnight under 5% CO₂ at 37° C. In day 2,100 μL of culture solution comprising a compound was added in each well.The plate was further incubated for 72 h under 5% CO₂ at 37° C.;

6. The culture solution was sucked out;

7. 100 μL of serum-free culture solution containing 0.5 mg/mL MTT wasadded in each well. The plate was incubated for 3 h;

8. The culture solution was carefully sucked out;

9. 100 μL of DMSO was added in each well and vibrated to dissolve;

10. OD values were determined at 490 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 13 Growth Inhibition Activity of Some Compounds in Examples on786-O Cells Inhibition Activity Compound (IC₅₀/nM) Compound A 180Example 62 110 Example 90 90

Example 13 DU-145 Cell Growth Inhibition Test (MTT Assay)

I. Assay Materials

Cell strains: DU-145 (prostate cancer cell strains); MTT: nitrobluetetrazolium; antitumor compounds; compound A:3′-pyrrolyldoxorubicin-14-oxo-succinic acid monoester; DMSO.

II. Reagents and Consumable Materials

Culture medium: 90% EMEM+10% FBS (fetal calf serum); Pancreatin (0.25%(w/v) solution was formulated with PBS, 0.53 mM of EDTA was added in theformulation); PBS; 96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. PBS was sucked out. 1.5 mL of 0.25% pancreatin was added to the plateto infiltrate the cells for 1 min;

4. The culture plate was placed in an incubator. Digestion was carriedout for about 1 min at 37° C.;

5. 3 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 mL) to give a uniform cell suspension. The suspension was implantedinto a 96-well cell culture disc by 4000 cells/100 μL per well. Theculture plate was incubated overnight under 5% CO₂ at 37° C. In day 2,100 μL of culture solution comprising a compound was added in each well.The plate was further incubated for 72 h under 5% CO₂ at 37° C.;

6. The culture solution was sucked out;

7. 100 μL of serum-free culture solution containing 0.5 mg/mL MTT wasadded in each well. The plate was incubated for 3 h;

8. The culture solution was carefully sucked out;

9. 100 μL of DMSO was added in each well and vibrated to dissolve;

10. OD values were determined at 490 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 14 Growth Inhibition Activity of Some Compounds in Examples onDU-145 Cells Inhibition Activity Compounds (IC₅₀/nM) Compound A 99Example 62 34 Example 89 56 Compound 90 30 Example 92 61

Example 14 Hep3B Cell Growth Inhibition Test (SRB Assay)

I. Assay Materials

Cell strains: Hep3B (liver cancer cell strains); SRB: 0.4% (w/v) workingsolution was formulated with 1% glacial acetic acid, reserved at 4° C.;antitumor compounds; compound A: 3′-pyrrolyldoxorubicin-14-oxo-succinicacid monoester; DMSO.

II. Reagents and Consumable Materials

Culture medium: 90% RPMI-1640+10% FBS; Pancreatin (0.25% (w/v) solutionwas formulated with PBS, 0.53 mM of EDTA was added in the formulation);PBS; 96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. 1.5 mL of 0.25% pancreatin was added to the plate to infiltrate thecells;

4. The pancreatin was sucked out. The culture plate was placed in anincubator. Digestion was carried out for about 3 min at 37° C.;

5. 4 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 mL) to give a uniform single cell suspension. The suspension wasimplanted into a 96-well cell culture plate by 5000 cells/100 μL perwell. The culture plate was incubated overnight under 5% CO₂ at 37° C.In day 2, 100 μL of culture solution comprising a compound was added ineach well. The plate was further incubated for 72 h under 5% CO₂ at 37°C.;

6. The culture solution was sucked out. 100 uL of TCA fixed cells whichwere diluted to 10% were added to each well. The plate was kept in arefrigerator for 1 h at 4° C.

7. TCA stationary liquid was sucked out. Each well was washed with 150μL of ddH₂O five times;

8. After the stationary liquid was cleansed, the plate was dried in theair at the room temperature;

9. 60 μL of SRB staining solution was added in each well. The well wasstained for 15 min at the room temperature;

10. The SRB staining solution was sucked out. Each well was washed with150 μL of 1% glacial acetic acid five times;

11. After the SRB staining solution was cleansed, the plate was dried inthe air at the room temperature;

12. 100 μL of 10 mM Tris was added in each well. The plate was vibratedto dissolve out SRB;

13. OD values were determined at 570 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of the compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 15 Growth Inhibition Activity of Some Compounds in Examples onHep3B Cells Inhibition Activity Compound (IC₅₀/nM) Compound A 444Example 90 29 Example 92 28

Example 15 SK-Br-3 Cell Growth Inhibition Test (SRB Assay)

I. Assay Materials

Cell strains: SK-Br-3 (human breast cancer cell strains); SRB: 0.4%(w/v) working solution was formulated with 1% glacial acetic acid,reserved at 4° C.; antitumor compounds; compound A:3′-pyrrolyldoxorubicin-14-oxo-succinic acid monoester; DMSO.

II. Reagents and Consumable Materials

Culture medium: 85% DMEM+15% FBS; pancreatin (0.25% (w/v) solution wasformulated with PBS, 0.53 mM of EDTA was added in the formulation); PBS;96-well culture plate.

III. Assay Process

1. A plate (10 cm) of cells in logarithmic growth phase that werenormally cultured was collected;

2. The culture solution was sucked out. The plate was washed with 5 mLof PBS once or twice;

3. 1.5 mL of 0.25% pancreatin was added to the plate to infiltrate thecells;

4. The pancreatin was sucked out. The culture plate was placed in anincubator. Digestion was carried out for about 2 min at 37° C.;

5. 4 mL of complete culture solution was added to the culture plate tostop the digestion. The cells were carefully scoured with micropipette(1 mL) to give a uniform single cell suspension. The suspension wasimplanted into a 96-well cell culture plate by 10000 cells/100 μL perwell. The culture plate was incubated overnight under 5% CO₂ at 37° C.In day 2, 100 μL of culture solution comprising a compound was added ineach well. The plate was further incubated for 72 h under 5% CO₂ at 37°C.;

6. The culture solution was sucked out. 100 uL of TCA fixed cells whichwere diluted to 10% were added to each well. The plate was kept in arefrigerator for 1 h at 4° C.

7. TCA stationary liquid was sucked out. Each well was washed with 150μL of ddH₂O five times;

8. After the stationary liquid was cleansed, the plate was dried in theair at the room temperature;

9. 60 μL of SRB staining solution was added in each well. The well wasstained for 15 min at the room temperature;

10. The SRB staining solution was sucked out. Each well was washed with150 μL of 1% glacial acetic acid five times;

11. After the SRB staining solution was cleansed, the plate was dried inthe air at the room temperature;

12. 100 μL of 10 mM Tris was added in each well. The plate was vibratedto dissolve out SRB;

13. OD values were determined at 570 nM.

IV. Results and Treatments

1. Calculation of Relative Inhibition RatioThe inhibition ratio of a compound on cell growth=(PC−n)/(PC−NC)×100%

wherein:

PC: OD values of cells after normal growth in control wells without acompound;

n: OD values of cells after growth in test wells with a compound;

NC: Background OD values of blank wells without a compound and cells.

TABLE 16 Growth Inhibition Activity of Some Compounds in Examples onSK-Br-3 Cells Inhibition Activity Compound (IC₅₀/nM) Compound A 93Example 98 15

Assay on MTD (Maxium Tolerated Dose) In Vivo of Mice

Assay on Maxium Tolerated Dose of Compound

Assay animals: mice of ICR strain with a weight of 18-22 g, purchasedfrom Beijing Vital River Laboratories Limited, License SCXK (jing)2007-0001.

Administration Regimen: each experimental animal was administered withcorresponding dosage of tested substance once by injection of caudalvain every three days. Each dosage was initially designed as 5 times ofadministration. The specific time of administration depended on theconditions of the animals. It should be carefully observed the behaviorconditions of the animals within 2 hours after administration. Theanimal's behavior was observed every 4 hours in the day ofadministration. The survival conditions and weight of animals wererecorded every day and observed for whether abnormality occurred on thebody surface thereof. The experimental animals were sacrificed on 14 dayafter administration and dissected for observation.

1. Tested Substance 1: 3′-pyrrolyldoxorubicin

1) Administration Groups

I group: (20 mg/kg) group;

II group: (25 mg/kg) group;

III group: (30 mg/kg) group;

IV group: solvent control group;

There were four groups in total. Each group consisted of five male miceand five female mice.

2) Assay Results

(1) The effects on weights of experimental animals are shown in FIG. 1.

(2) The effects on survival ratio of experimental animals are shown inTable 17.

TABLE 17 Number of Number Total Animals per of Dead Mortality DosageTimes of Dosage Group Animals Rate (mg/kg) Administration (mg/kg) ♂/♀♂/♀ (%) 20 4 80 5/5 5/5 100 25 4 100 5/5 5/5 100 30 3 90 5/5 5/5 100Control 4 0 5/5 0/0 0 Note: ♂: male mouse; ♀: female mouse

3) Assay Results and Discussions

The experimental animals in the solvent control group exhibited normallyincreased weight without death. Death occurred in succession in theexperimental animals after administration with 20 mg/kg or 25 mg/kg fourtimes. Death occurred in succession in the experimental animals afteradministration with 30 mg/kg three times. The mortality rate is 100%.The MTD of the tested compound 1 is less than 20 mg/kg (0.0338 mmol/kg)according to the q4d×5 administration regimen.

Tested Compound 2: the compound of Example 96

1) Administration Groups

I group: (40 mg/kg) group;

II group: (45 mg/kg) group;

III group: (50 mg/kg) group;

IV group: (55 mg/kg) group;

V group: (60 mg/kg) group;

There were five groups in total. Each group consisted of six male miceand six female mice.

2) Assay Results

(1) The effects on weights of experimental animals are shown in FIG. 2.

(2) The effects on survival ratio of experimental animals are shown inTable 18.

TABLE 18 Number of Number Total Animals per of Dead Mortality DosageTimes of Dosage Group Animals Rate (mg/kg) Administration (mg/kg) ♂/♀♂/♀ (%) 40 5 200 6/6 0/1 8.33 45 5 225 6/6 0/0(1/2a) 0 50 5 250 6/60/0(1/1a) 0 55 5 275 6/6 5/4(5/3a) 25 60 5 300 6/6 3/4 53.85 Note: ♂:male mouse; ♀: female mouse

a represents that the experimental animal died immediately after theinjection of drug rather than death caused by cytotoxicity. The animalwhich died immediately after administration was not counted in thecalculation of mortality rate (mortality rate=the number of experimentalanimals which did not die immediately after injection/(the number ofanimals in group−the number of experimental animals diedimmediately)×100%).

3) Assay Results and Discussions

There was one dead animal in the 40 mg/kg dosage group. The mortalityrate is 8.33%. The dead animal was dissected for observation of variousorgans. The organs did not exhibit obvious abnormality. However, therewas several bite marks on the surface of the skin of the dead animal.This animal did not have significant weight loss. Therefore, it ispresumed that the death is caused by cytotoxicity factor rather thandrug. Two experimental animals died immediately after the fifthadministration in the 50 mg/kg dosage group. The two dead animals didnot have significant weight loss. It is presumed that the death iscaused by cytotoxicity factor rather than drug. The MTD of the testedcompound 2 is 50-55 mg/kg (0.0525-0.0578 mmol/kg) according to the q4d×5administration regimen.

3. Tested Substance 3: 3′-pyrrolyldoxorubicin-14-oxo-succinic acidmonoester

1) Administration Groups

I group: (30 mg/kg) group;

II group: (40 mg/kg) group;

III group: (50 mg/kg) group;

IV group: (60 mg/kg) group;

There were four groups in total. Each group consisted of five male miceand five female mice.

2) Assay Results

(1) The effects on weights of experimental animals are shown in FIG. 3.

(2) The effects on survival ratio of experimental animals are shown inTable 19.

TABLE 19 Number of Number Total Animals per of Dead Mortality DosageTimes of Dosage Group Animals Rate (mg/kg) Administration (mg/kg) ♂/♀♂/♀ (%) 30 5 150 5/5 0/1 10 40 5 200 5/5 3/2 50 50 5 250 5/5 5/5 100 605 300 5/5 5/5 100 Note: ♂: male mouse; ♀: female mouse

3) Assay Results and Discussions

The lethality rates of mice of ICR strain are 10%, 50%, 100%, 100%respectively, according to the administration regimens of 30 mg/kg, 40mg/kg, 50 mg/kg, 60 mg/k of compounds. One experimental animal driedwithout significant weight loss in the animals of 30 mg/kg group,indicating that this dead animal in 30 mg/kg group does not exclude thecause of animal's individual difference. The MTD of the tested compound3 is approximately 30 mg/kg (0.0433 mmol/kg) according to the q4d×5administration regimen.

The above general description regarding the invention disclosed hereinand the description of the specific embodiments thereof cannot beconstrued as the limitation to the technical solutions of the invention.One of ordinary skill in the art can add, delete or combine thetechnical features disclosed in the above general description and/orspecific embodiments (including Examples) to form other technicalsolutions within the invention according to the disclosure hereinwithout departing from the constitutive elements of the invention.

What is claimed is:
 1. A compound represented by formula (I) and apharmaceutically acceptable salt thereof,

wherein: R¹ is selected from the group consisting of H, optionallysubstituted alkyl, and optionally substituted alkoxy; R² is selectedfrom the group consisting of H, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted (alkyleneoxy)_(m)alkyl,optionally substituted heterocyclyl, optionally substituted alkyl, andoptionally substituted —S(═O)₂R; R³ is selected from the groupconsisting of H, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted (alkyleneoxy)_(m)alkyl, optionallysubstituted heterocyclyl, optionally substituted alkyl, and optionallysubstituted —S(═O)₂R; or NR²R³ represents optionally substitutedheterocyclyl; wherein R comprises optionally substituted alkyl,optionally substituted cyclohydrocarbyl, optionally substitutedheterocyclyl, optionally substituted aryl, or optionally substitutedheteroaryl; m is selected from the group consisting of 0, 1, 2, 3, 4, 5,6, 7, 8, 9, 10, and 11; W is selected from the group consisting of O andNH; R⁴ is selected from the group consisting of H, F, and optionallysubstituted alkyl; R⁵ is selected from the group consisting of H, F,optionally substituted alkyl and OR⁶, wherein R⁶ is selected from thegroup consisting of H and tetrahydropyran-2-yl; and n is selected fromthe group consisting of 1, 2 and
 3. 2. The compound of claim 1, whereinR¹ is selected from the group consisting of H and OCH₃.
 3. The compoundof claim 1, wherein W is O.
 4. The compound of claim 1, wherein R⁴ isCH₃.
 5. The compound of claim 1, wherein R⁵ is selected from the groupconsisting of OH and (tetrahydropyran-2-yl)oxy.
 6. The compound of claim1, wherein R² is selected from the group consisting of H, methyl, ethyl,(morpholinylmethyl)phenyl, 4-((morpholin-1-yl)methyl)phenyl,(dimethylaminomethyl)phenyl, 4-((dimethylamino)methyl)phenyl,2-(2-(dimethylamino)ethoxy)ethyl, morpholin-1-yl, piperidin-1-yl,tetrahydropyrrol-1-yl, 4-(2-hydroxyethyl)piperazin-1-yl,(4-methylpiperazin)-1-yl, (4-ethylpiperazin)-1-yl,2-(tetrahydropyrrol-1-yl)ethyl, 3-(tetrahydropyrrol-1-yl)propyl,(2-(morpholin-1-yl)pyridin)-4-yl, (2-(morpholin-1-yl)pyridin)-5-yl,pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, (pyridin-4-yl)methyl,(pyridin-3-yl)methyl, (pyridin-2-yl)methyl, 2-(pyridin-4-yl)ethyl,2-(pyridin-3-yl)ethyl, 2-(pyridin-2-yl)ethyl, 2-(pyridin-4-yl)propyl,2-(pyridin-3-yl)propyl, 2-(pyridin-2-yl)propyl,2-((4-sulfamido)phenyl)ethyl, (3-(dimethylamino)propyl)piperazin-1-yl,3-((4-sulfamido)phenyl)propyl, 3-((4-methyl)piperazin-1-yl)propyl,3-((4-ethyl)piperazin-1-yl)propyl, 3-((4-propyl)piperazin-1-yl)propyl,2-((4-methyl)piperazin-1-yl)ethyl, 2-((4-ethyl)piperazin-1-yl)ethyl,2-((4-propyl)piperazin-1-yl)ethyl, 2-(dimethylamino)ethyl,2-(diethylamino)ethyl, 2-(dipropylamino)ethyl, 2-(piperidin-1-yl)ethyl,2-(morpholin-1-yl)ethyl, 2-(tetrahydropyrrol-1-yl)ethyl,3-(dimethylamino)propyl, 3-(diethylamino)propyl,3-(dipropylamino)propyl, 3-(piperidin-1-yl)propyl,3-(morpholin-1-yl)propyl, 3-(tetrahydropyrrol-1-yl)propyl,4-(dimethylamino)butyl, 4-(diethylamino)butyl, 4-(dipropylamino)butyl,4-(piperidin-1-yl)butyl, 4-(morpholin-1-yl)butyl,4-(tetrahydropyrrol-1-yl)butyl,2-(2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(diethylamino)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(dipropylamino)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(piperidin-1-yl)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(morpholin-1-yl)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(tetrahydropyrrol-1-yl)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethyl,2-(2-(2-(diethylamino)ethoxy)ethoxy)ethyl,2-(2-(2-(dipropylamino)ethoxy)ethoxy)ethyl,2-(2-(2-(piperidin-1-yl)ethoxy)ethoxy)ethyl,2-(2-(2-(morpholin-1-yl)ethoxy)ethoxy)ethyl,2-(2-(2-(tetrahydropyrrol-1-yl)ethoxy)ethoxy)ethyl, 6-purinyl, mesyl,benzenesulfonyl, pyrazin-2-yl, pyrimidin-2-yl, 2-hydroxyethyl,2-(2-hydroxyethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,and 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl.
 7. The compound ofclaim 1, wherein R³ is selected from the group consisting of H, methyl,ethyl, (morpholinylmethyl)phenyl, 4-((morpholin-1-yl)methyl)phenyl,(dimethylaminomethyl)phenyl, 4-((dimethylamino)methyl)phenyl,2-(2-(dimethylamino)ethoxy)ethyl, morpholin-1-yl, piperidin-1-yl,tetrahydropyrrol-1-yl, 4-(2-hydroxyethyl)piperazin-1-yl,(4-methylpiperazin)-1-yl, (4-ethylpiperazin)-1-yl,2-(tetrahydropyrrol-1-yl)ethyl, 3-(tetrahydropyrrol-1-yl)propyl,(2-(morpholin-1-yl)pyridin)-4-yl, (2-(morpholin-1-yl)pyridin)-5-yl,pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, (pyridin-4-yl)methyl,(pyridin-3-yl)methyl, (pyridin-2-yl)methyl, 2-(pyridin-4-yl)ethyl,2-(pyridin-3-yl)ethyl, 2-(pyridin-2-yl)ethyl, 2-(pyridin-4-yl)propyl,2-(pyridin-3-yl)propyl, 2-(pyridin-2-yl)propyl,2-((4-sulfamido)phenyl)ethyl, (3-(dimethylamino)propyl)piperazin-1-yl,3-((4-sulfamido)phenyl)propyl, 3-((4-methyl)piperazin-1-yl)propyl,3-((4-ethyl)piperazin-1-yl)propyl, 3-((4-propyl)piperazin-1-yl)propyl,2-((4-methyl)piperazin-1-yl)ethyl, 2-((4-ethyl)piperazin-1-yl)ethyl,2-((4-propyl)piperazin-1-yl)ethyl, 2-(dimethylamino)ethyl,2-(diethylamino)ethyl, 2-(dipropylamino)ethyl, 2-(piperidin-1-yl)ethyl,2-(morpholin-1-yl)ethyl, 2-(tetrahydropyrrol-1-yl)ethyl,3-(dimethylamino)propyl, 3-(diethylamino)propyl,3-(dipropylamino)propyl, 3-(piperidin-1-yl)propyl,3-(morpholin-1-yl)propyl, 3-(tetrahydropyrrol-1-yl)propyl,4-(dimethylamino)butyl, 4-(diethylamino)butyl, 4-(dipropylamino)butyl,4-(piperidin-1-yl)butyl, 4-(morpholin-1-yl)butyl,4-(tetrahydropyrrol-1-yl)butyl,2-(2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(diethylamino)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(dipropylamino)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(piperidin-1-yl)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(morpholin-1-yl)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(tetrahydropyrrol-1-yl)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethyl,2-(2-(2-(diethylamino)ethoxy)ethoxy)ethyl,2-(2-(2-(dipropylamino)ethoxy)ethoxy)ethyl,2-(2-(2-(piperidin-1-yl)ethoxy)ethoxy)ethyl,2-(2-(2-(morpholin-1-yl)ethoxy)ethoxy)ethyl,2-(2-(2-(tetrahydropyrrol-1-yl)ethoxy)ethoxy)ethyl, 6-purinyl, mesyl,benzenesulfonyl, pyrazin-2-yl, pyrimidin-2-yl, 2-hydroxyethyl,2-(2-hydroxyethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl,and 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl.
 8. The compound ofclaim 1, wherein NR²R³ is selected from the group consisting ofpiperidin-1-yl, morpholin-1-yl, tetrahydropyrrol-1-yl,(4-(2-hydroxyethyl))piperazin-1-yl, (4-methyl)piperazin-1-yl,(4-ethyl)piperazin-1-yl, (4-propyl)piperazin-1-yl,4-(3-hydroxypropyl)piperazin-1-yl, 3-(morpholin-1-yl)propyl,adenin-1-yl, (4-(3-(dimethylamino)propyl)piperazin)-1-yl,(4-(2-(dimethylamino)ethyl)piperazin)-1-yl,(4-(3-(diethylamino)propyl)piperazin)-1-yl,(4-(2-(diethylamino)ethyl)piperazin)-1-yl,(4-(2-(piperidin-1-yl)ethyl)piperazin)-1-yl,(4-(3-(piperidin-1-yl)propyl)piperazin)-1-yl,(4-(2-(morpholin-1-yl)ethyl)piperazin)-1-yl,(4-(3-(morpholin-1-yl)propyl)piperazin)-1-yl,(4-(2-(tetrahydropyrrol-1-yl)ethyl)piperazin)-1-yl, and(4-(3-(tetrahydropyrrol-1-yl)propyl)piperazin)-1-yl.
 9. A compoundselected from the group consisting of:

wherein W is O, R¹ is OCH₃, R⁴ is CH₃, R⁵ is OH, n and NR²R³ are shownin the following table:

No. n NR²R³  1 3

 2 2

 3 3

 4 2

 5 3

 6 2

 7 3

 8 2

 9 3

10 2

11 3

12 2

13 3

14 2

15 3

16 2

17 3

18 2

19 3

20 2

21 3

22 2

23 3

24 2

25 3

26 2

27 3

28 2

29 3

30 2

31 3

32 2

33 3

34 2

35 3

36 2

37 3

38 2

39 3

40 2

41 3

42 2

43 3

44 2

45 3

46 2

47 3

48 2

49 3

50 2

51 3

52 2

53 3

54 2

55 3

56 2

57 3

58 2

59 3

60 2

61 3

62 2

63 3

64 2

65 3

66 2 NH₂ 67 3 NH₂ 68 2 NHCH₃ 69 3 NHCH₃ 70 2 N(CH₃)₂ 71 3 N(CH₃)₂ 72 2

73 3

74 2

75 2

88 2

90 2

91 2

92 2

93 2

94 2

95 2

77)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((4-(2-hydroxy)ethyl)piperazin-1-yl)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate; 78)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((3-(morpholin-1-yl)propyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate; 79)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((4-methyl)piperazin-1-yl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate; 80)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(4-ethylpiperazin-1-yl)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate; 81)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate; 82)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((pyridin-4-yl)methyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate; 83)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((pyridin-3-yl)methyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate; 84)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(pyridin-2-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate; 85)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(pyridin-3-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate; 86)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(2-(pyridin-4-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate; 87)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-(4-(3-(dimethylamino)propyl)piperazin-1-yl)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate; 89)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((2-(morpholin-1-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedioneacetate; 96)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((2-(morpholin-1-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedionephosphate; and 99)10-((3′-(pyrrol-1-yl)-2′,3′,6′-trideoxy-alphal-L-lyxo-hexylpyranyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-13-oxo-14-(4-((2-(morpholin-1-yl)ethyl)amino)-4-oxo-butyrato)-1-methoxy-5,12-naphthalenedionehydrochloride.
 10. A process for preparing a compound represented byformula (I) of claim 1, comprising

reacting a compound represented by formula (II) with a compoundrepresented by formula (III) in the presence of a condensation agent toobtain a compound represented by formula (I), wherein: R¹ is selectedfrom the group consisting of H, optionally substituted alkyl, andoptionally substituted alkoxy; W is selected from the group consistingof O and NH; R⁴ is selected from the group consisting of H, F, andoptionally substituted alkyl; R⁵ is selected from the group consistingof H, F, optionally substituted alkyl and OR⁶, wherein R⁶ is selectedfrom the group consisting of H and tetrahydropyran-2-yl; n is selectedfrom the group consisting of 1, 2 and 3; R⁷ and R⁸ are independentlyselected from the group consisting of H, optionally substituted aryl,optionally substituted heteroaryl, optionally substituted(alkyleneoxy)_(m)alkyl, optionally substituted heterocyclyl, optionallysubstituted alkyl, and optionally substituted —S(═O)₂R, provided thatgroups represented by R⁷ and R⁸ do not comprise NH or NH₂; or NR⁷R⁸represents optionally substituted heterocyclyl; wherein R comprisesoptionally substituted alkyl, optionally substituted cyclohydrocarbyl,optionally substituted heterocyclyl, optionally substituted aryl, oroptionally substituted heteroaryl; and m is selected from the groupconsisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11; and optionally,contacting the compound represented by formula (III) having anamino-protecting group at N-terminus with a deprotection reactant toconduct a deprotection reaction to obtain the compound represented byformula (I), where the group represented by R⁷ or R⁸ comprises NH orNH₂.
 11. The process of claim 10, further comprising adding a catalyst.12. The process of claim 11, wherein the catalyst is selected from4-dimethylaminopyridine, 4-pyrrolidinylpyridine and a mixture thereof.13. The process of claim 10, wherein the amino-protection group isselected from the group consisting of Fmoc (fluorenylmethoxycarbony),Boc (t-butyloxycarboryl), CBZ (carbobenzoxy), Tr (trityl), Alloc(allyloxycarbonyl), Teoc (trimethylsilylethoxycarbonyl),methoxycarbonyl, ethoxycarbonyl, Pht (phthaloyl), Tos (tosyl), Ns(o/p-nitrobenzenesulfonyl), Tfa (trifluoroacetyl), pivaloyl, benzoyl,Dmb (2,4-dimethoxybenzyl), PMB (p-methoxybenzyl), and Bn (benzyl). 14.The process of claim 10, wherein the condensation agent is selected fromthe group consisting of dicyclohexylcarbodiimide (DCC),diisopropylcarbodiimide (DIC),1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI),2-(7-azobenzotriazole)-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HATU), benzotriazol-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HBTU), 6-chlorobenzotriazol-1,1,3,3-tetramethyluroniumhexafluorophosphate (HCTU),O-(7-azabenzotriazol-1-yl)-di(tetrahydropyrrolyl)carbeniumhexafluophosphate (HAPyU),O-(benzotriazol-1-yl)-di(tetrahydropyrrolyl)carbenium hexafluophosphate(HBPyU), O-benzotriazol-N,N,N′,N′-tetramethyluronium tetrafluoroborate(TBTU), 2-succinimido-1,1,3,3-tetramethyluronium tetrafluoroborate(TSTU), 2-(5-norbornen-2,3-dicarboximido)-1,1,3,3-tetramethyluroniumtetrafluoroborate quaternary ammonium salt (TNTU),benzotriazol-1-yloxytri(dimethylamino)phosphonium hexafluorophosphate(BOP), benzotriazol-1-yl-oxytripyrrolidino-phosphoniumhexafluorophosphate (PyBOP),(3H-1,2,3-triazolo[4,5-b]pyridin-3-oxy)tri-1-pyrrolidinylphosphoniumhexafluorophosphate (PyAOP), diphenylphosphinyl chloride (DPP-Cl),diphenyl phosphoryl azide (DPPA), cyanodiethylphosphate (DECP),bis(2-oxo-3-oxazolidinyl)phosphinyl chloride (BOP-Cl) and mixturesthereof.
 15. The process of claim 10, wherein the deprotection reactantis selected from the group consisting of hydrogen gas, NH₃,aminoethanol, dimethylamine, diethylamine, piperidine, piperazine,1,8-diazacyclo[5,4,0]hendecene-7 (DBU), hydrochloric acid, phosphoricacid, acetic acid, formic acid, trifluoroacetic acid, methanesulfonicacid, benzenesulfonic acid, p-toluenesulfonic acid and mixtures thereof.16. The process of claim 10, wherein the compound represented by formula(III) is obtained by a reaction of a compound represented by formula(IV) with HNR⁷R⁸,

wherein: n is selected from the group consisting of 1, 2 and 3; R⁷ andR⁸ are independently selected from the group consisting of H, optionallysubstituted aryl, optionally substituted heteroaryl, optionallysubstituted (alkyleneoxy)_(m)alkyl, optionally substituted heterocyclyl,optionally substituted alkyl, and optionally substituted —S(═O)₂R; orNR⁷R⁸ represents optionally substituted heterocyclyl; wherein Rcomprises optionally substituted alkyl, optionally substitutedcyclohydrocarbyl, optionally substituted heterocyclyl, optionallysubstituted aryl, or optionally substituted heteroaryl; and m isselected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,and
 11. 17. The process of claim 16, further comprising adding analkaline compound.
 18. The process of claim 17, wherein the alkalinecompound is selected from the group consisting of triethylamine,pyridine, diisopropylethylamine, trimethylamine, N-methylpyrrolidine,N-methylpiperidine, N-methylmorpholine, N-ethylpyrrolidine,N-ethylpiperidine, N-ethylmorpholine and mixtures thereof.
 19. Theprocess of claim 10, further comprising adding an activator.
 20. Theprocess of claim 19, wherein the activator is selected from the groupconsisting of N-hydroxysuccinimide (HOSu), 1-hydroxy-7-azobenzotriazole(HOAt), 1-hydroxybenzotriazole (HOBt), N-hydroxyphthalimide (NHPI),N-hydroxy-1,8-naphthalimide (NHNI), pentafluorophenol (PFPOH),2-(7-azobenzotriazole)-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HATU), benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HBTU), 6-chlorobenzotriazole-1,1,3,3-tetramethyluroniumhexafluorophosphate (HCTU),O-(7-azabenzotriazole-1-yl)-di(tetrahydropyrrolyl)carbeniumhexafluophosphate (HAPyU),O-(benzotriazole-1-yl)-di(tetrahydropyrrolyl)carbenium hexafluophosphate(HBPyU), O-benzotriazole-N,N,N′,N′-tetramethyluronium tetrafluoroborate(TBTU), 2-succinimido-1,1,3,3-tetramethyluronium tetrafluoroborate(TSTU), 2-(5-norbornen-2,3-dicarboximido)-1,1,3,3-tetramethyluroniumtetrafluoroborate quaternary ammonium salt (TNTU),benzotriazole-1-yloxytri(dimethylamino)phosphonium hexafluorophosphate(BOP), benzotriazol-1-yl-oxytripyrrolidino-phosphoniumhexafluorophosphate (PyBOP),(3H-1,2,3-triazolo[4,5-b]pyridin-3-oxy)tri-1-pyrrolidinylphosphoniumhexafluorophosphate (PyAOP), diphenylphosphinyl chloride (DPP-Cl),diphenyl phosphoryl azide (DPPA), cyanodiethylphosphate (DECP),bis(2-oxo-3-oxazolidinyl)phosphinyl chloride (BOP-Cl) and mixturesthereof.
 21. A formulation, comprising a compound represented by formula(I) of claim 1 or a pharmaceutically acceptable salt thereof, and apharmaceutically acceptable carrier.
 22. The formulation of claim 21,which is a formulation for injection.
 23. The process of claim 22,wherein the formulation for injection is a conventional powderinjection, a freeze-dried powder injection, a hydro-injection, anemulsion, a solution or a suspension.
 24. A method for treating tumorand/or cancer, comprising administering to a subject in need thereof atherapeutically effective amount of the compound represented by formula(I) of claim 1 or a pharmaceutically acceptable salt thereof; whereinthe tumor and/or cancer is selected from the group consisting of livercancer, breast cancer, small cell lung cancer, large cell lung cancer,ovarian cancer, pancreatic cancer, kidney clear cell adenocarcinoma,epidermal carcinoma, melanoma, and prostatic cancer.